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1 Summary
The transcription factor liver X receptor alpha (LXRa), a member of the nuclear re-
ceptor family, is a key factor that regulates intracellular cholesterol homeostasis and
inhibit inflammatory gene expression. LXR agonists have been considered as promising
anti-atherosclerotic drugs, and several natural or synthetic LXR ligands are currently
under investigation for pharmaceutical develoment. Macrophages and lipid-loaded
macrophage foam cells are an early and persistent component of atherosclerotic lesions
and likely play an important role in disease progression. However, LXRa-dependent
genome-wide regulation of target genes in human macrophages remained incompletely
elucidated. This thesis was addressed to correlate global ChIP-sequencing-derived
LXRa cistromes and gene expression profiles to investigate the effects of LXRa ac-
tivation on direct and putative indirect LXRa target genes. Moreover, the recruit-
ment mechanisms whereby LXRa selects genomic regions and interacts with the
chromatin landscape were studied. These analyses were carried out using THP-1
cell-derived differentiated macrophages, and oxidized low density lipoprotein (oxLDL)
triggered macrophage-derived foam cells that were exposed to the synthetic LXR ag-
onist T0901317. The results of this thesis revealed that LXRa DNA binding is not
restricted to gene promoters but appears predominantly at distal enhancer regions.
LXRa cistromes in macrophages and foam cells are largely distinct although a number
of genes were commonly occupied. Correlation of LXRa cistromes and gene expression
data confirmed known and defined novel direct LXRa target genes. It also revealed
that LXRa cooperates with and directly regulates other transcription factors including
retinoic acid receptor alpha (RARa) and activator protein 1 (AP-1). To regulate gene
expression LXRa binds to DNA in a ligand-dependent way and the majority of func-
tional binding events is targeted to regions of accessible chromatin and transcription
factor hotspots. Together, the results of this thesis define a basis for understanding
regulatory factor-genome interactions, provide a framework for the effects of LXR
activation, and how to develop optimized LXR agonists.
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2 Introduction
Heart disease and stroke – cardiovascular disease – are the largest cause of sickness
and morbidity and a major cause of death for the citizens of the EU and the Western
world (Leal et al. 2006). Cardiovascular disease currently costs the European health
system more then 500 million euro each day, and these costs are likely to escalate over
the next few years. Atherosclerotic plaque rupture and subsequent luminal thrombus
formation are considered the major step in the development of acute cardiovascular
events (Carson 2010). Therefore, atherosclerosis has been the subject of an immense
amount of basic and applied research.
Atherosclerosis is considered as a multifactorial, multistep disease with various
processes that have to act together to initiate and promote atherosclerotic development.
Fatty streaks, accumulation of cholesterol-loaded macrophages in the arterial wall,
are a hallmark of early atherosclerotic lesions that gradually thickens the arterial
wall and may ultimately lead to major blockage of blood flow (Libby 2002). The ligand
sensitive transcription factor liver X receptor alpha (LXRa) is involved in signalling
pathways that clearly display anti-atherogenic properties by regulating cholesterol
homoeostasis, as well as metabolic and inflammatory signal integration. Advances
in our knowledge of the molecular mechanisms underlying lipid metabolism and its
regulation by transcription factors may have an enormous effect on the prevention and
treatment of this major health issue.
2.1 Macrophage foam cells and atherosclerosis
The development of fatty streaks is initiated by endothelial dysfunction, possibly caused
by traumatic damage, infectious microorganisms, free radicals caused by cigarette
smoking, elevated oxidized low-density lipoprotein cholesterol (oxLDL) or other fac-
tors (Ross 1999). Endothelial activation results in expression of adhesion molecules,
chemokines and cytokines, leading to adherence of circulating monocytes and subse-
quent monocyte recruitment into the subendothelial space of the vascular wall. Within
the artery wall monocytes differentiate into macrophages and take up oxLDL, which
2
itself acts as major chemoattractant (Li and Glass 2002). The modification of native
lipoproteins is required for the recognition by macrophage scavenger receptors and
several lines of evidence suggest that macrophages and endothelial cells promote LDL
oxidation in the presence of high LDL levels (Skalen et al. 2002). In macrophages, this
process involves myeloperoxidase (MPO), NADPH oxidase and the nitric oxide syn-
thases (iNOS) as means to generate antimicrobial reactive oxygen species. Therefore,
macrophages contribute to the amplification of oxidative reactions and promote lesion
initiation and progression (Li and Glass 2002). As macrophages convert the imported
cholesterol into the ester form, they become filled with cholesteryl ester lipid droplets,
resulting in foam cell formation. In response to cholesterol over-loading, macrophages
activate different compensatory pathways. Endogenous, cholesterol and lipid biosyn-
thesis is repressed by inhibition of the sterol regulatory element-binding transcription
factor 1 (SREBF1) pathway (Yoshikawa et al. 2001). As cells cannot degrade cholesterol,
it is exported to extracellular acceptors for transport to the liver for biliary excretion.
These acceptors include apolipoproteins apolipoprotein A-I (APOA1), apolipoprotein E
(APOE) and high-density lipoprotein (HDL) particles (Beyea et al. 2007). The cellular
cholesterol efflux is mediated through ATP-binding cassette transporters ABCG1 and
ABCA1 to protect the cells from cholesterol overload (Oram and Heinecke 2005, Wang
et al. 2007). In the face of continuous cholesterol uptake homeostatic mechanisms
are overwhelmed, leading to enhanced macrophage foam cell formation and further
recruitment of monocytes. The transition of fatty streak lesions to more advanced
lesions further involves the production of cytokines and other signalling molecules
by macrophages and other cells within the arterial wall leading to the migration of
smooth muscle cells into the subendothelial space. Smooth muscle cells synthesize
collagen, fibrin and proteoglycans leading to the formation of the fibrous cap found in
advanced atherosclerotic lesions (Glass and Witztum 2001). Apoptosis and necrosis
of macrophage and smooth muscle cells further lead to necrotic cores. Necrotic cores
surrounding macrophages secrete matrix metalloproteinases that degrade the collagen
of the endothelium causing its rupture and subsequent platelet recruitment that initi-
ates thrombus formation (Lee and Libby 1997). Taken together, lipid metabolism and
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immune responses in macrophages play a crucial role in the progression of atheroscle-
rotic plaque development. Insights into the mechanisms underlying the macrophage
responses are required to develop novel therapeutic strategies for prevention and
treatment of atherosclerosis.
2.2 Liver X receptors
LXRa (NR1H3) (Willy et al. 1995) and LXRb (NR1H2) (Song et al. 1994) are members
of the nuclear receptor transcription factor superfamily. Nuclear receptors are a unique
group of transcription factors that all act as sensors for hormonal and metabolic signals.
Therefore, ligands such as steroids, thyroid hormones, cholesterol derivatives and fatty
acids bind and therefore activate the receptor leading to gene expression regulation
of nuclear receptor specific target genes. The largest subfamily NR1 includes LXR,
peroxisome proliferator-activated receptor (PPAR), thyroid hormone receptor (TR),
retinoic acid receptor (RAR) and RAR-related orphan receptor (ROR) (Germain et al.
2006).
LXRs are master regulators of cholesterol homoeostasis, metabolic and inflam-
matory pathways and are commonly known as cholesterol sensors (Peet et al. 1998).
In macrophage foam cells LXR activation is triggered by oxLDL-derived oxysterols
(Janowski et al. 1999). Moreover, synthetic agonists such as T0901317 were developed
that activate LXRs. This has made LXRs an established tool to investigate molecular
mechanisms of transcriptional regulation. In humans LXRa and LXRb share almost
80% amino acid identity in their DNA-binding domain and ligand-binding domain.
Amongst both LXR isoforms, LXRa is highly expressed in the liver and at lower levels
in intestine, adipocytes and macrophages. In contrast, LXRb is expressed ubiquitously
(Zelcer and Tontonoz 2006). The known role of LXR expands with the growing num-
ber of studies. Therefore, LXRs are also implicated in de-novo cholesterol synthesis,
detoxification of bile acids and lipids, glucose homoeostasis, skin homoeostasis and
neurological functions (Viennois et al. 2011).
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2.3 Mechanism of LXR target gene regulation
As other nuclear receptors of the NR1 family, LXRs form obligate heterodimers with
the retinoic X receptor (RXR). Activation of the heterodimer complex can be induced by
ligands for either RXR or LXR (Lu et al. 2001). RXR-LXR heterodimers bind to specific
DNA sequences, LXR response elements (LXREs), consisting of two direct repeats
of hexanucleotides separated by a spacer of four nucleotides (Repa and Mangelsdorf
1999). Three different mechanisms of transcriptional regulation of target genes have
been categorized. First, LXR-RXR heterodimers can actively repress gene expression
in the absence of a ligand by the recruitment of co-repressor complexes, including
silencing mediator of retinoic acid and thyroid hormone receptor (SMRT), nuclear
receptor co-repressor (N-CoR) and histone deacetylases (HDACs) (Hu et al. 2003).
Second, in the presence of a ligand, conformation changes of the receptors lead to
displacement of co-repressors and the subsequent recruitment of co-activators such as
activating signal cointegrator-2 (ASC-2) (Lee et al. 2008), steroid receptor co-activator
1 (SRC-1) (Son and Lee 2010) and histone acetyl transferases (Viennois et al. 2011)
leading to target gene transcription. Third, LXR ligand activation can inhibit gene
expression by trans-repression as shown for the nuclear factor kB (NF- kB) (Wu et al.
2009).
2.4 LXR in mouse models
LXR dependent signalling pathways clearly display anti-atherogenic properties, both
by reducing cholesterol levels and supressing anti-inflammatory genes. In mouse
models for atherosclerosis (LDLR-/- and apoE-/-) bone marrow transplantation of cells
from LXRa/b-/- mice lead to significantly greater atherosclerotic lesion development
compared to their counterparts that received bone marrow cells from wild-type mice
(Tangirala et al. 2002). The central importance for macrophage LXRs in atherosclerosis
was further confirmed by the finding that LXRa/b-/- mice exhibit increased cholesterol
accumulation in arterial wall macrophages even on normal diet. Consistently, activa-
tion of LXR by synthetic agonists leads to protection and regression of atherosclerotic
lesions (Joseph et al. 2002). Importantly, LXRa was shown to be required for positive
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agonist effects in mice (Levin et al. 2005) and macrophage-specific over-expression of
LXRa ameliorated atherosclerosis in mice, independent of synthetic agonist treatment
(Li et al. 2011).
2.5 LXR-dependent regulation of gene expression
If cellular oxysterols accumulate as a result of elevated concentrations of cholesterol,
LXR induces the transcription of genes that protect cells from cholesterol overload.
Thus, investigations of LXR-dependent gene expression regulation in macrophages
revealed its involvements in cholesterol absorption, transport, and elimination. LXR
activation leads to induced expression of ABCA1 (Qiu and Hill 2008), ABGG1 (Lee
et al. 2010) and APOE (Bradley et al. 2007) in macrophages mediating cholesterol
efflux, which facilitates cholesterol transport to extracellular receptors APOAI and
HDL. Moreover, HDL levels are increased by direct LXR induction of phospholipid
transfer protein (PLTP) that contributes to HDL formation and therefore accelerates
cholesterol transport to the liver (Laffitte et al. 2003). LXR also reduces LDL uptake by
inhibiting the LDL receptor pathway through the transcriptional induction of myosin
regulatory light chain interacting protein (MYLIP) (Zelcer et al. 2009a). On the other
hand, LXR directly up-regulates sterol regulatory element-binding transcription factor
1 (SREBF1) that induces transcription of genes related to lipid biosynthesis (Ferre
and Foufelle 2007). Positive regulation of lipid biosynthesis associated genes through
LXR-RXR heterodimer binding in macrophages is also described for fatty acid synthase
(FASN), fatty acid desatuase (FADS), stearoyl-CoA desaturase (SCD) and elongation
of very long chain fatty acids protein 5 (ELOVL5) (Schultz et al. 2000, Repa et al.
(2000), Wang et al. 2004, Qin et al. 2009). Interestingly, LXRs and SREBF1 bind to and
activate many of the same genes involved in de novo fatty acid biosynthesis including
FASN (Shibata and Glass 2010). FASN contributes to the synthesis of free fatty
acids used for cholesterol esterification of free cholesterol by sterol O-acyltransferases
(SOATs) that protect cells from toxic effects of free cholesterols (Repa et al. (2000)).
Taken together, LXRs activation and regulation of specific target gens antagonizes
the process of cholesterol accumulation by promoting cholesterol efflux resulting in
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enhanced reverse cholesterol transport to the liver.
2.6 LXRa as therapeutic targets
As described above, accumulation of cholesterol in macrophages is considered a pri-
mary event in the development of atherosclerosis. Thus removal of excess cholesterol
from differentiated macrophages and macrophages-derived foam cells is important for
prevention and treatment of atherosclerotic cardiovascular diseases. The abundant ex-
pression of LXRa in macrophages present in human atherosclerotic lesions (Watanabe
et al. 2005) and the observations from targeted LXRa over-expression in mice (Li et al.
2011) support the hypothesis that specific LXRa agonists could have a positive effect
against development of atherosclerosis (Zhao and Dahlman-Wright 2010). Despite
the positive effects on atherosclerosis in mouse models, targeting LXR for therapeutic
purposes in humans must overcome the obstacle of LXR-induced hepatic steatosis
in mice (Joseph et al. 2002). Additionally, it is not clear how good the results from
mouse studies will be predictive of potentially targeting LXRa pathways in humans for
therapy.
In spite of many advances in previous studies in different human cell lines, the com-
plete list of direct target genes for LXR remains elusive. Only a subset of known LXR
target genes was elucidated specifically in human macrophage models by single gene
approaches. Moreover, LXR binding was mainly shown by reporter assays independent
of the endogenous genomic background. Those approaches were also restricted to genes
associated with clear LXR-RXR consensus binding sequences. Importantly, existing
studies primarily focused on LXRb or detected binding regardless of the LXR isoforms.
Therefore, until now, no published study has uncovered genome–wide LXRa-DNA
binding and target gene regulation in human macrophages.
2.7 Aims of this thesis
The purpose of this thesis is to obtain a better understanding of the mechanisms
of actions of LXRa in human macrophages during atherosclerosis. Therefore, LXRa
binding and gene expression changes will be analysed in THP-1 cell-derived differ-
7
entiated macrophages and oxLDL-triggered macrophage-derived foam cells under
T0901317-induced LXRa activation as compared with untreated macrophages.
Independently, data from chromatin immunoprecipitation experiments coupled
with high-throughput sequencing (ChIP-seq) and data from expression microarray
experiments tell very different stories. ChIP-seq structurally measures protein-DNA
binding that can be used to hypothesize gene regulation by their locations in the
genome. Microarray experiments provide a functional view on changes in gene expres-
sion regardless of exact regulatory mechanisms. However, the integration of data from
both approaches allows the assignment of specific regulatory roles of transcription
factors.
Therefore, treatment–specific LXRa cistromes will be determined using genome-
wide LXRa occupancy data. Then, cistromes are integrated with genome-wide tran-
scription data to obtain a global view of directly regulated target genes and to construct
a network of transcriptional regulators influenced by LXRa activation. Since LXRa is
involved in various aspects of metabolism in macrophages, an important question is
whether it binds the same genomic regions in different macrophage treatment models.
Alternatively, LXRa may bind to treatment specific regions, allowing the regulation of
specialized pathways. Another important aspect is the mechanism whereby LXRa se-
lects genomic regions and interacts with the chromatin landscape leading to target gene
regulation. It has previously been shown that transcription factor binding correlates
with nucleosome-depleted regions of open chromatin that represent active regulatory
elements (Gaulton et al. 2010). Therefore, chromatin accessibility that accompanies
the binding of LXRa will be investigated using high-throughput sequencing of genomic
regions enriched by formaldehyde-assisted isolation of regulatory elements (FAIRE-
seq). This analysis also enables investigations regarding the specific co-regulator
requirement of functional LXRa binding sites. Collectively, this master’s thesis aims to
provide an initial framework for understanding and investigating LXRa-dependent
gene regulations in human macrophages by the use of integrative analysis strategies.
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3 Results
3.1 LXRa is up-regulated in response to the LXR agonist T0901317
Several studies showed that LXRa but not LXRb transcription is influenced by an
auto-up-regulatory loop. Therefore, LXRa occupies the LXR-response element in the
LXRa gene leading to transcriptional up-regulation upon agonist application. Thus,
LXRa activity is influenced not only by specific ligands alone but also by changes in
transcription factor expression (Li et al. 2002, Whitney et al. 2001). The auto-regulation
of LXRa provides a mechanism for amplifying the effects of endogenous oxLDL in
macrophages to promote cholesterol efflux in order to attenuate the transformation of
macrophages into foam cells (Whitney et al. 2001). To estimate the amount of ligand
specific LXRa up-regulation and to confirm previous findings, expression analysis
was performed to estimate LXRa protein levels amongst untreated and T0901317-
treated differentiated THP-1 cells and T0901317-treated THP-1-derived foam cells. In
accordance with previous results (Laffitte et al. 2001) western blot analysis revealed
that LXRa gene expression is induced by T0901317. Coadministration of the natural
ligand oxLDL and T0901317 showed an additive effect with strongly up-regulated
LXRa protein expression. Contrary, in the absence of ligand LXRa expression was
hardly detectable (Figure 1A). Measured mRNA levels support these observations in
THP-1 cells (Figure 1B).
3.2 ChIP-seq analysis of LXRa binding
Chromatin-immunoprecipitation and sequencing experiments can quantify the asso-
ciation of a DNA-ineracting protein with every position in the genome. Therefore,
proteins are crosslinked with DNA and the isolated chromatin is fragmented before
immunoprecipitating the protein-DNA complexes and reversing the crosslinks (Leleu
et al. 2010). LXRa ChIP-seq experiments were previously performed in our lab and the
obtained data sets were used to identify genomic loci bound by LXRa. The ChIP-derived
material was therefore subjected to library preparation followed by next generation




Figure 1: LXRa is up-regulated in macrophages and foam cells in response to
T0901317. (A) Equal amounts of proteins from nuclear extracts were subjected to
western blot analysis using antibodies against LXRa and b-actin (Actin). Differentiated
THP-1 cells were treated either with 0.01% DMSO (Control) or 1 µM T0901317 (T09)
for 24 hours or with 100 µg/ml oxLDL for 48 hours and 1 µM T0901317 for 48 hours
(T09 + oxLDL). (B) Microarray measures of LXRa transcript expression levels. Bar
graphs indicate relative expression between treated (T09 and T09 + oxLDL ) and
vehicle-treaded (Control) cells. Data were normalized to the intensity of b-actin as a
housekeeping gene. Each point represents the mean of triplicate values ± standard
derivation.
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3.2.1 ChIP-seq-derived LXRa binding profiles confirm known LXRa target
genes
Aligned sequencing reads were processed to generate density profiles, which were
examined across loci corresponding to six known LXRa target genes. Profiles from
LXRa-induced cells showed LXRa binding with a clear enrichment of tags over a narrow
range near loci of LXRa itself and the genes such as ABCA1, ACCA, FASN, SREBF1
and ABCG1 (Figure 2A). These binding regions were not detected if cells were not
treated with LXRa-specific ligands. In order to confirm the robustness of the ChIP-seq
data, LXRa ChIP was repeated and the enriched material was assessed using real-time
quantitative PCR (qPCR). Visual comparison of the ChIP-seq profiles confirmed high
concordance. Binding of LXRa was tested at ten genomic regions in LXRa-induced THP-
1-derived macrophages and no binding was observed in the absence of LXRa activation
(Figure 2B). In accordance with the ChIP-seq profiles, enhanced signals at binding
sites were observed in T0901317-treated foam cells compared to T0901317-treated
macrophages.
In addition to binding sites close to the gene transcriptional start sites, LXRa
enriched regions were observed in distal putative enhancer regions (ABCA1) and in
intronic regions of target genes (ABCG1 and LXRa, Figure 2A). Remarkably, alternative
promoters of SREBF1 were individually occupied by LXRa, indicating stringent splice
variant regulation. Together, these observations show that LXRa binds to different
genomic sites to regulate the same target gene and that binding is not restricted to
proximal target promoter regions. Distal binding sites indicate the possibility of remote
transcription factor interaction through DNA looping or protein tethering, which also
challenges the definition of target genes especially in regions with high gene densities
(Nolis et al. 2009, Zhao et al. 2011).
3.2.2 Genome-wide identification of LXRa binding sites
Identification of unknown LXRa target sites and determination of treatment specific
changes of LXRa occupancy requires genome-wide determination of LXRa enriched
regions. This task is accomplished by using peak calling algorithms that output
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Figure 2: LXRa occupancy at genomic regulatory elements. (A) LXRa ChIP-seq
profiles of genomic loci for the LXRa target genes ABCG1, LXRa, ABCA1, ACCA, FASN
and SREBF1. Clear LXRa enrichments are detected in promoter and enhancer regions
of gene loci on T0901317-treated macrophages (T09, red) and foam cells (oxLDL + T09,
green), whereas no binding is observed in the absence of ligand (Control, blue) or at
negative control regions (2, 5, 8). ChIP-seq data are plotted as the density of 25-bp tags
mapping to the region. The y axis represents the estimated number of tags at each
position. Gene loci are shown based on the human genome February 2009 assembly
(GRCh37/hg19) in the UCSC browser using RefSeq positions. The direction of transcrip-
tion is shown by the arrow beginning at the TSS. Genomic coordinates of the shown
regions: ABCG1 (chr21:43,608,584-43,654,980), LXRa (chr11:47,270,159-47,280,387),
ABCA1 (chr9:107,622,630-107,834,119), ACCA (chr17:35,708,974-35,769,074), FASN
(chr17:80,053,735-80,059,108) and SREBF1 (chr17:17,725,865-17,742,257). (B) ChIP-
qPCR validation of LXRa enrichment at sites indicated by numbers below ChIP-seq
profiles (A). Data are fold enrichments compared to individual input non-enriched DNA
normalized to IgG ChIP DNA. The data are the mean of triplicate values ± standard
derivation. Negative control region are indicated (NC).
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positions in the genome with more ChIP-seq tags than expected by chance and thus
identify genomic intervals of enriched regions as observed at LXRa target gene loci
(Figure 3A). Peak intervals were identified genome-wide by the use of the model based-
analysis of ChIP-seq (MACS) algorithm (Zhang et al. 2008) with LXRa sequencing data
against control IgG ChIP-seq data. Therefore, aligned tags of two biological replicates
from T0901317-treated macrophages and untreated macrophages were individually
pooled to gain sufficient tag enrichment and to correct for biological variations. The
algorithm successfully determined peak intervals at already observed enrichment
sites of known LXRa targets. MACS also indicated the absence of LXRa binding in
uninduced cells as the derived peak intervals had very low tag enrichments and low
peak significances compared to binding sites detected in cells after LXRa activation.
Nevertheless, broad fractions of estimated peak intervals of all three data sets showed
low significance levels (Figure 3B). Therefore, candidate peaks from data of LXRa-
induced cells were filtered by removing those peak intervals that were inconsistent
between three individual peak identification runs using data from different IgG-
ChIP samples. Those peak intervals were further filtered using k-means clustering
(Heintzman et al. 2009) to remove clusters of intervals with low tag enrichments.
Filtering defined a high-confidence set of genome-wide LXRa binding sites with 249
and 215 peak intervals of TO901317-stimulated THP-1-derived macrophages and foam
cells respectively. Strikingly, only 64 peak intervals are shared in both treatment
models upon LXRa activation (Figure 4A).
3.2.3 LXRa binding is induced upon LXRa activation
The observation from sequencing-derived profiles and qPCR validation experiments
that show the absence of LXRa binding in untreated THP-1 control cells was also
encouraged by the low genome-wide sequencing coverage (Figure 5A). In concert, heat
map visualisation of tag densities around LXRa peak intervals from both macrophage
treatment models show only marginal tag accumulations in untreated THP-1-derived
macrophages (Figure 4B, control). To further investigate these observations, average
tag profiles centered at LXRa binding sites were estimated along with sequencing data
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Figure 3: Peak detection and significance of peaks. (A) Peak detection and tag
density profile generation. Aligned ChIP-seq-derived forward (red) and reverse (blue)
tags (Tags) generate a strand-specific pattern that is used for the detection of enriched
regions via peak calling algorithms (Peak interval, green). For visualization tag lo-
cations are extended by an estimated fragment size in the appropriate orientation
and the number of fragments is counted at each position to generate a density profile
(Profile, black). Tag density profiles are plotted as the density of 25-bp tags mapping
to the region. The y axis of the profile represents the estimated number of tags at
each position. Shown is the ABCA1 promoter region (~2kb). (B) Box plot showing
the distributions of ChIP-Seq peak interval significances (-10*Log10(p-value)) deter-
mined by MACS from vehicle-treated macrophages (Control, blue), T0901317-treated
macrophages (T09, red) and T0901317-treated foam cells (oxLDL + T09, green).
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Figure 4: Ligand-dependent dynamics of LXRa. (A) Comparison of large-scale
ChIP profiling data. Venn diagram of the overlap of LXRa-binding sites of T0901317-
treated macrophages (T09, red) and T0901317-treated foam cells (oxLDL + T09, green)
as identified by MACS and filtered as described (Methods). 64 of the ChIP-Seq interac-
tion sites are overlapping with at least 1 base pair. (B) Heat maps show enrichment
over all 400 sorted LXRa binding sites (LXRa Peak), where the shading corresponds to
the LXRa ChIP-seq and IgG ChIP-seq read count in the region from vehicle-treated
macrophages (Control, blue), T0901317-treated macrophages (T09, red) and T0901317-
treated foam cells (oxLDL + T09, green). One-kilobase pairs around the LXRa peaks
are displayed.
from input DNA. Sequencing of fragmented chromatin that was de-crosslinked and
not subjected to immunoprecipitation generated these input DNA. Input DNA is often
used as control in ChIP-Seq experiments as alternative to nonspecific IgG antibodies
(Kidder et al. 2011). Remarkably, average tag density profiles at LXRa binding sites
of cells that were not exposed to LXRa agonists are similar to tag profiles derived
from input DNA samples (Figure 5B). This shows that the minor tag accumulations
in untreated cells do not represent indications of LXRa binding and rather reflect
inherent sequencing bias, mapping ambiguity or chromatin structure as described
previously (Vega et al. 2009).
These findings indicate strictly ligand-induced LXRa binding in differentiated THP-
1 cells contrary to the classic model of constitutive LXR binding and replacement of
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LXR associated co-repressors with co-activators upon ligand-induced LXR activation
(Wagner et al. 2003, Hu et al. 2003). Importantly, even different LXRa activation
strategies by T0901317 treatment or combinatorial treatment with T0901317 and
oxLDL lead to differential binding patterns as observed from heat map visualisation,
LXRa peak interval intersection (Figure 4) and at specific loci (Figure 5C). The conven-
tional mechanism of constitutive LXRa binding was recently challenged by the findings
that LXRa/b recruitment was entirely ligand-dependent at the ABCG1 promoter in
HepG2 and THP-1 cells (Jakobsson, 2009). However, absence of basal LXRa binding in
untreated cells may be cell line or LXR isoform specific and did not reflect the situation
in untreated primary human macrophages where basal LXRa occupancy was detected
by ChIP-qPCR (Figure 5D). Additionally, it cannot be ruled out that LXRa binding
in untreated THP-1 cells is simply not detectable by ChIP assays due to low levels
of LXRa protein in those cells compared to others. Though, LXRa activation by diet-
dependent endogenous stimuli is much more likely in primary human cells compared
to vehicle-treated macrophages-derived from the THP-1 cell line. However, the global
absence of LXRa binding in control cells represents an appropriate macrophage model
to study ligand-induced binding upon LXRa activation.
3.2.4 LXRa binds proximal promoter regions and distal regulatory elements
Defined LXRa binding sites were enriched at promoters and coding exons relative to
their genomic frequency illustrating that LXRa binds in regions directly associated
with transcriptional regulation. The observed preponderance of binding occurred at
putative enhancer regions intronic and distal intergenic with nearly unchanged occu-
pancy relative to the genomic frequency (Figure 6A). Precise distance analysis of LXRa
peaks relative to genes confirmed these observations and showed accumulation close
to promoters with the occurrence of distal binding in T0901317-treated differentiated
macrophages and foam cells (Figure 6B). Similar results were obtained by peak distri-
bution analysis relative to gene bodies (not shown). Collectively and in accordance with
initial profile inspections, results show that LXRa has widespread distribution patterns
similar to other transcription factors (Welboren, 2009) and cannot be categorized to
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Figure 5: Influence of ligand application on LXRa DNA binding. (A) LXRa
ChIP-seq sequence depth in differently treated macrophages including biological
replicates (BR). (B) Average LXRa ChIP-seq tag profile at LXRa binding sites of
T0901317-treated macrophages (left) and T0901317-treated foam cells (right) show
tag enrichment in treated cells (T0901317 and T09 + oxLDL). In vehicle-treated cells
(DMSO) tag enrichment is similar to sequenced input DNA (Input). Three-kilobase
pairs around the LXRa peaks are displayed. (C) Ligand-induced cell model specific
LXRa binding sites (peak intervals shown as black bars) at three representative gene
loci (JUN: chr1:59,226,758-59,353,087, RARa: chr17:38,461,237-38,491,262 and CD14:
chr5:140,007,968-140,023,959). ChIP-seq data are plotted as the density of 25-bp tags
mapping to the region. The y axis represents the estimated number of tags at each
position. The UCSC Genes track is used to indicate RefSeq validated gene positions.
(D) ChIP-qPCR of LXRa enrichment at the LXR response element in proximity to the
FASN promoter in primary human monocyte-derived macrophages and THP-1 cells.
Data are fold enrichments compared to individual input non-enriched DNA normalized
to IgG ChIP DNA. The data are the mean of triplicate values ± standard derivation.
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Figure 6: Genomic distribution of LXRa binding sites. (A) Distribution of
LXRa binding sites over genomic features for T0901317-treated macrophages (T09)
and T0901317-treated foam cells (T09 + oxLDL). The percentages of the mappable
regions that are located in genomic features (genome background) is shown (Genome).
Promoters are defined as TSS ± 3 kb. ‘Intergenic’ represents the percentage of ChIP
regions that do not belong in any of other genomic features. (B) LXRa ChIP-seq peak
distribution relative to known TSS (RefGene) ± 500 kb (red: T09, green T09 + oxLDL).
either proximal promoter or enhancer binding.
3.2.5 A global inventory of LXRa occupied genes
One of the major challenges in ChIP-seq analysis represents mapping transcription
factor binding to the genes they regulate directly, considering the three-dimensional
structure of chromatin (Dekker 2008) but also the heterogeneous gene annotation
resources (Sherman et al. 2007). A known gene with a proximal transcription factor
binding site around its promoter region is usually considered as a direct target gene
because proximal transcription factor binding is often manifested by changes in gene
expression (Loh et al. 2006). The vast proportion of binding sites located away from
transcriptional start sites, challenge the connection of those sites to the corresponding
targets. However, to begin to examine the functional significance of LXRa binding
on a genome-wide scale, LXRa binding sites were annotated to the nearest gene
using gene annotations from the NCBI RNA reference sequences collection (RefSeq).
That identified 226 and 197 genes targeted by 249 and 215 LXRa binding events in
agonist treated THP-1-derived macrophages and foam cells respectively (Tables 1
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and 2). The observed reduction from number of binding sites to number of genes is
explained by the fact that LXRa binds at more than one site near or within a gene as
previously shown by tag density profile inspection. Regions of multiple binding sites
in both treatment groups were exclusively associated with the known LXRa target
genes ABCA1, ABCG1, SCD, APOC1, SREBF1 and RARa. Thus, the presence of
multiple binding sites in close proximity indicates a mechanism of stringent target
gene regulation. Investigation of the functional relationship of LXRa target genes
revealed significant associations to lipid, fatty acid and cholesterol metabolic pathways.
Furthermore, functional enrichment analysis (Sherman et al. 2007) showed genes
that were associated to pathways not directly connected with the common functions of
LXRa, suggesting a wider role of LXRa in other biological processes (Table 3).
3.3 LXRa binding triggers differential expression
of distinct gene sets
Hypothetically, genes that are stringently modulated by LXRa would contain a LXRa
enriched region in their vicinity and show altered regulation of gene expression. To
address a broad range of genes that are potentially regulated, genomic binding sites
were therefore extensively annotated using different approaches that were combined
and finally correlated with treatment-dependent expression changes. Using microarray
technology gene expression profiles were generated from isolated RNA of THP-1 cells
that were treated in the same manner as cells used for ChIP assays. The comparison
of the profiles between untreated THP-1-derived macrophages with both T0901317-
treated macrophages and T0901317-treated foam cells revealed that 332 and 942 genes
were significantly changed for both treatment conditions respectively.
The performed next gene analysis was restricted to a single gene that is next to
a binding site (Table 1 and 2). However, it remains possible that one binding site
regulates one or many target genes. The observed ligand-induced co-expression of
the neighbouring genes ACP2 (1.4-fold) and LXRa (2.7-fold) that are targeted by only
one LXRa binding event support the assumption that an individual binding site may
influence a set of surrounding genes. Therefore, the single nearest gene annotation
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Table 1: Top 50 LXRa binding sites of T0901317-treated macrophages.
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Table 2: Top 50 LXRa binding sites of T0901317-treated foam cells
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Table 3: Functional clustering of nearest gene datasets of T0901317-treated
macrophages (A) and T0901317-treated foam cells (B) by the DAVID gene onthol-
ogy program.
approach was combined with determination of peak surrounding proximal genes and
the association of distal peak intervals with genes in regulatory domains by the use
of binomial and hypergeometric tests (McLean et al. 2010). This relaxed annotation
strategy considered ~460 putatively LXRa-associated genes in both treatment models.
Comparison of LXRa occupied genes with genes that were significantly differentially
expressed upon ligand stimulation, identified an array of 52 genes in both macrophage
conditions that are refered to as direct LXRa target genes. Within these sets 20
and 40 genes were classified by LXRa binding and expression changes in T0901317-
treated macrophages and foam cells respectively (Table 4 and 5). The majority of the
direct LXRa target genes were up-regulated but four genes in T0901317-treated foam
cells were down-regulated. These findings confirm that LXRa acts as transcriptional
activator as well as repressor (Hu et al. 2003) but also highlights, that direct LXRa
target gene regulation preferentially leads to activation of transcription. Only eight
up-regulated genes were shared amongst both models, elucidating the distinct role
of LXRa in differentiated macrophages and oxLDL-induced foam cells upon LXRa
activation.
However, the most obvious conclusion of the performed correlation is that only
a very distinct gene set is directly regulated by LXRa. The majority of LXRa bound
genes and a large portion of differentially expressed genes is not clearly correlated with
direct LXRa regulation. This raises the possibility that LXRa acts through long-range
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mechanisms, indirect via other transcription factors, or that many of the LXRa binding
events are opportunistic.
3.3.1 Previously unknown LXRa target genes
Gene ontology classification (Sherman et al. 2007) was used to identify biological
processes that would be over-represented amongst directly regulated LXRa target
genes. Directly regulated target genes fall in the already determined categories,
including cholesterol efflux, metabolism of lipids and fatty acid metabolism (Figure 4
and 5). Many of those genes represent known LXRa targets, although direct binding in
human macrophages by the use of ChIP assays was only shown for a small minority,
such as the LXRa target genes ABCG1 and ABCA1 (Jakobsson et al. 2009). However,
data mining in biological databases revealed a number of detected genes that are
not yet associated with LXRa, such as acid sphingomyelinase-like phosphodiesterase
3A (SMPDL3), endonuclease/exonuclease/phosphatase family domain containing 1
(EEPD1) and amiloride-sensitive cation channel 3 (ACCN3). Interestingly, many of
the directly regulated LXRa target genes in T0901317-treated foam cells represent
membrane proteins. Categorization of gene sets by gene families additionally revealed
the presence of directly regulated transcription factors. Many of those were not yet
shown to be direct targets of LXRa.
3.3.2 Correlation of LXRa binding and gene expression changes in different
treatment models
To better understand how LXRa binding and gene expression correlate between
T0901317-treated macrophages and foam cells, both gene lists were combined and
sorted according to common and treatment specific genes. Remarkably, diverse combi-
natorial clusters were observed, regarding LXRa binding and associated gene expres-
sion (Table 6). The comparison indicates, that LXRa binding alone is not sufficient to
gain gene expression changes in both treatment models (cluster III and V) and vice
versa (cluster IV and II). As expected, combinatorial treatment of T0901317 and oxLDL-
derived foam cells induces LXRa binding at almost all gene loci whereas T0901317
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Table 4: Overview of direct LXRa target genes in T0901317-treated
macrophages. Shown are differentially expressed genes that show LXRa binding
within a maximum distance of 200 kb. More than one gene was annotated if the LXRa
binding sites was within a maximum distance of 30 kb (*). Additionally, genes were
estimated by the use of Genomic Regions Enrichment of Annotations Tool (**) (McLean
et al. 2010). Functional annotations and disease associations were derived using




Table 5: Overview of direct LXRa target genes in T0901317-treated foam cells.
See table 4 for description.
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treatment alone induces only a subset of the joined gene loci. Thus, especially genes of
cluster VI show highly differential LXRa binding, illustrated at the JUN locus (Figure
5C). Interestingly, many membrane-associated proteins fall into this category and
show LXRa binding and differential expression only in the foam cell model. The other
way around, many genes associated with fatty acid synthesis are only differentially
expressed under T0901317 treatment although LXRa binding is also present in foam
cells.
Excessive literature mining is necessary to estimate the biological context of these
observations in detail and some examples are described below. Together, presence
of combinatorial clusters as observed in both treatment models suggests that LXRa-
dependent regulation is embedded in a more complex framework that controls regula-
tion of distinct gene sets.
3.4 LXRa directly regulates other transcription factors
Expression microarrays showed that hundreds of genes are differentially expressed
upon LXR-specific agonist treatment but only a small number of the genes were directly
regulated by LXRa binding. Target gene determination demonstrates that in addition
to direct gene regulation, LXRa regulates other transcription factors indicating that
LXRa controls a network of responses to activating synthetic and endogenous ligands.
Therefore, to investigate the complexity of LXRa target gene regulation, both direct
and putative indirect target genes were considered by the use PMW (position weight
matrix) over-representation analysis and publicly available interaction profiles of the
THP-1 cell line provided by the FANTOM (Functional Annotation of the Mammalian
Genome) consortium (Kawaji et al. 2010). The FANTOM4-EdgeExpress Database (fan-
tom.gsc.riken.jp) is an easily queriable tool to perform network predictions. Network
analysis using only direct LXRa target genes revealed interactions of transcription
factors including LXRa, retinoic acid receptor alpha (RARa), NRIP1, JUN and MNT but
also non-transcription factor targets that generate a rich set for future investigations
(Figure 7).
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Table 6: Comparison of LXRa binding and gene expression changes. LXRa
target genes of T0901317-treated macrophages and T0901317-treated foam cells.
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Figure 7: Interaction network analysis of direct LXRa target genes. All esti-
mated direct LXRa target genes of T0901317-treated macrophages (A) and T0901317-
treated foam cells (B) are shown. All shown feature properties are estimated by the
use of the FANTOM4-EdgeExpress Database. Legend: Edge colours: Black: Transcrip-
tion factor binding site predictions and miRNA target predictions; Yellow: Published
protein-DNA edges; Purple: Protein-protein interactions; Red: siRNA and miRNA
perturbation edges. Edge line style: Solid: Direct edges; Dashed: perturbation edges
(possibly direct or indirect). Edge terminators: Arrowhead: activating relationships;
Round: bidirectional protein-protein relationships. The diameter of each node is scaled
to indicate the dynamics of gene expression. Highly dynamic nodes are larger than
statically expressed nodes. The color of the node is mapped to a relative scale for each
node between white for min(expression) and purple max(expression). If the node has
no detectable expression, the name of the node becomes red and the background is
white (fantom.gsc.riken.jp).
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Table 7: Functional clustering of putatively RARa-regulated genes from the PWM
network analysis using the DAVID gene onthology program.
3.4.1 RARa putatively contributes to indirect gene regulation by LXRa
To investigate the extent of indirect LXRa targets, ChIP-seq and microarray expression
profiling data were combined with a genome-wide search for over-represented motifs of
the transcription factors directly targeted by LXRa. Therefore, promoters of differen-
tially expressed genes were scanned using PWMs followed by filtering based on the
conservation of the motifs (Qin et al. 2011). PWMs are a collection of motifs that are
similar, but not identical to the transcription factor specific consensus sequence and
are commonly used to predict transcription factor binding (Klepper et al. 2008). The
analysis determined that the direct LXRa target RARa putatively regulates 34 genes,
differently expressed in THP-1-derived macrophages exposed to T0901317 (Figure 8).
The overlap of RARa motifs in the promoter of those genes was significant (P-value
4.3*10-12), which indicates that overlapping does not happen randomly. The associated
gene set is enriched in diverse metabolic processes and signal transduction pathways
(Table 7) and includes five additional transcription factors.
Interestingly, the genes SREBF1, FASN and ACCA were identified as common
targets for LXRa and RARa, indicating that both are involved in their regulation.
Contrary to the situation in T0901317-treated macrophages; expression of those targets
and RARa is not significantly changed in T0901317-treated foam cells but LXRa binding
is observed in both conditions. This observation may give some evidence that RARa is
required for up-regulation of those common target genes that are implicated in lipid
biosynthesis contributing to side effects of LXRa agonists in the liver. However, also
other pathways were elucidated that attenuate up-regulation of SREBF1, FASN and
ACCA in foam cells (Rowe et al. 2003).
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Figure 8: PWM-based regulatory interactions. Transcriptional regulatory net-
work showing direct targets of LXRa (NR1H3) including RARa. The regulon of RARa
is determined by scanning all promoters of differentially expressed genes with PWM
(position weight matrix) of the transcription factors (triangles) from three accessible
databases, JASPAR, UniPROBE and UCSC genome browser TFBS track (Qin et al.
2011). Red: up-regulated. Blue: down-regulated. Analysis was performed from data of
T0901317-treated macrophages.
The same analysis in T0901317-treated foam cells did not reveal indications for
indirect target gene regulation based on PWMs. Thus, the results of the PWM-based
analysis in macrophages give some evidence for a possible cross-talk between two
nuclear receptors upon T0901317 treatment. However, further functional assays are
required to prove this initial observations.
3.4.2 T0901317 and oxLDL-induced differences in gene regulatory networks
To further expand the observations from the PWM-based analysis, interacting genes
in both, T0901317-treated macrophages and foam cells were linked to regulatory
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networks. Therefore, all genes with a significant change in transcript abundance in
treated cells versus untreated cells were selected. Those genes were integrated with
known and experimentally validated protein-protein and protein-DNA interactions
and results from high throughput siRNA knockdown experiments in THP-1 cells using
the FANTOME web resources (Kawaji et al. 2010).
The analysis highlights that a complex network of transcription factors is regulated
in T0901317-treated foam cells and macrophages (Figure 9 and 10). Additionally, it
shows a stringent but restricted role of LXRa within this network. It must be noted
that in total 74 and 37 transcription factors are differentially expressed upon T0901317
treatment in both macrophage models, respectively. Of those factors at least MNT and
JUN in T0901317-treated foam cells and SREBF1 in T0901317-treated macrophages
are characterized as direct LXRa target genes that gather a vast number of putatively
regulated genes.
In addition to regulating cholesterol metabolism, LXRs are also negative regulators
of macrophage inflammatory gene responses (Shibata and Glass 2009). Interestingly,
36 (p-value 2.8E-8) genes associated with inflammatory responses are repressed in
T0901317-treated foam cells, including NFKB1 (0.3-fold) and IL-1b (0.4-fold). Those
genes are not directly targeted by LXRa. This suggests the possibility and confirms
previous observations that the anti-inflammatory properties of LXRa are generally me-
diated through indirect LXRa-dependent mechanisms. Similarly, network visualisation
elucidated the down-regulation of RXRa indicating that LXRa negatively regulates its
own obligate dimerization partner through indirect pathways. Collectively, the motif
based and interaction based identification of putative indirect LXRa target genes high-
lights that a complex network of regulatory responses is triggered by ligand application
in both macrophages models.
3.5 Chromatin status and transcription factor binding
To understand the role of chromatin accessibility in regulating LXRa binding and
target genes, sites of localized chromatin remodelling were profiled using FAIRE
assays. FAIRE is a simple high-throughput method to determine active regulatory
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Figure 9: Network predictions of T0901317-induced response in THP-1 cells
(1). Functional network which connects the identified directly bound LXRa target genes
with the global transcriptional T0901317-induced response of macrophages (Figure
9) and foam cells (Figure 10). Basic networks at the top and bottom are equal and
show genes that are differentially expressed. Top: Only direct LXRa target genes are
colored according to gene expression. Node colors indicate expression levels of genes.
The node size is proportional to the relative connectivity to other factors (dominated by
transcription factors). Description continued in caption of figure 10.
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Figure 10: Network predictions of T0901317-induced response in THP-1
cells (2). The grey lines (edges) indicate interactions derived from the FANTOM4-
EdgeExpress Database. Interactions are assembled from siRNA perturbation and
ChIP-seq experiments in THP-1 cells and published data. Additionally, interactions
are calculated using expression patterns of mRNAs, microRNAs, and gene promoters
in THP-1 cells and publicly available protein-protein and protein-DNA interaction
predictions (Kawaji et al. 2010). The size of NR1H3 does not represent its connectivity.
Genes without connectivity (singletons) are not shown.
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elements based on their decreased nucleosomal content. Nucleosomes are the most
abundant and readily crosslinkable component of chromatin and therefore dominate
the crosslinking profile compared to other DNA binding proteins (Giresi et al. 2007).
FAIRE assays involve crosslinking proteins to DNA using formaldehyde, shearing
the chromatin, and performing a phenol–chloroform extraction. The enrichment of
protein-free DNA fragments that preferentially segregate into the aqueous phase are
then analysed using qPCR or high-throughput sequencing (Giresi and Lieb 2009).
3.5.1 LXRa binding coincides sites of highly accessible chromatin
FAIRE-qPCR signals were initially examined within selected proximal promoter re-
gions and distal putative enhancer elements of validated LXRa regulated genes. As
shown in Figure 11, LXRa occupied sites were enriched in FAIRE isolated DNA com-
pared to control regions. FAIRE signals at LXRa binding sites near FASN, SREBF1
and LXRa were small but significantly increased in THP-1-derived macrophages upon
T0901317-induced LXRa activation. Contrary, an increase in DNA accessibility was
not evaluated in T0901317-treated foam cells. When FAIRE-qPCR was employed to
compare DNA accessibility at the same regions in primary macrophages, markedly
increased FAIRE signals were observed upon ligand treatment. This observation
may indicate that primary cells undergo enhanced chromatin remodelling compared
to THP-1 cells. Interestingly, FAIRE enrichments in primary macrophage-derived
foam cells showed induced open chromatin at LXRa binding sites corresponding to
LXRa and ABCA1 but not FASN, SREBF1 and ACCA. These results correlate with the
altered gene expression of the examined genes. Thus, LXRa binding at sites of induced
open chromatin is connected to up-regulation of gene expression of LXRa (7.3-fold)
and ABCA1 (10.1-fold). In contrast, LXRa binding to sites of unchanged chromatin
accessibility is connected with unchanged transcript abundance for FASN, SREBF1
and ACCA. However, the overall FAIRE-enrichment at functional LXRa binding sites
indicates that chromatin accessibility is required for efficient LXRa binding and target
gene regulation as described for other transcription factors (Eeckhoute et al. 2009, Left-
erova et al. 2010). This suggests that genome-wide identification of FAIRE enriched
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Figure 11: LXRa binding correlates with DNA accessibility. FAIRE-qPCR on
THP-1 cells and primary human monocyte-derived macrophages (pMF) at indicated
LXRa binding sites (LXRa BS) of LXRa target genes (FASN, SREBF1, LXRa and
ABCA1) and negative control regions (NC). FAIRE values were normalized against
those measured for three loci at the b-actin promoter (Reference). E rror bars indicate
the SE of three samples (THP-1, measured in two to three biological replicates) or the
mean of triplicate values ± standard derivation (pMF, measured in three technical
replicates). (A) Box-whisker plots of FAIRE-qPCR including values at binding sites
not shown in (B). (B) Representative FAIRE-enrichments. Cells were vehicle-treated
(Control, blue), treated with T0901317 (T09, red), or T0901317-treated after foam cell
induction (T09 + oxLDL).
sites would be an important predictor for functional LXRa-dependent regulation.
3.5.2 Proximal transitions in chromatin structures accompany LXRa bind-
ing events
FAIRE was coupled to high-throughput sequencing to gain a global view on accessible
regions of chromatin and to classify functional LXRa binding events with high confi-
dence. Following sequencing, 27-31 million uniquely mappable reads were obtained
indicating consistent sample purity. Generated FAIRE tag signal profiles, representing
nucleosome-depleted chromatin regions, together with LXRa binding profiles are shown
35
in figure 12 for three representative LXRa target gene loci. The profiles confirm that
LXRa binding events co-occur with regions of open chromatin that define active regula-
tory elements. Additionally, the FAIRE profiles highlight the presence of large numbers
of adjacent regulatory elements that are not occupied by LXRa. Interestingly, those
sites of open chromatin show strong treatment-dependent changes whereas LXRa bind-
ing coincides constitutively open sites at selected target genes (SREBF1 and ABCG1).
Similar patterns were recognized at other LXRa target gene loci. These observations
may indicate that additional factors act in concert to regulate gene expression at the
observed gene loci under different treatment conditions. Thus, in contrast to LXRa,
these factors seem highly influenced by local chromatin remodelling events. How-
ever, gene loci targeted by multiple LXRa binding events show treatment-dependent
chromatin remodelling at LXRa occupied regions with various combinatorial patterns
(Figure 12, ABCA1). At the ABCA1 locus, combinatorial patterns of open chromatin
may define those LXRa binding sites that contribute to gene regulation. This highlights
the possibility that genes targeted by multiple binding events can be regulated in a
more complex fashion in response to external stimuli.
3.5.3 Quantitative relationship between LXRa binding and open chromatin
To quantify the relation of LXRa binding and chromatin status, genomic regions with
high chromatin accessibility over background were delineated with liberal stringency
(Gaulton et al. 2010) and ~176k sites were identified encompassing 2.2% of the genome
(~60 Mb). Non-promoter sites of open chromatin (94%) showed dynamic treatment-
dependent changes while promoter-associated sites (6%) were relatively constant.
Therefore, a small overlap (25%) for all liberal treatment specific open chromatin sites
was determined. The overlap was strongly enhanced (62%) if 10.000 rank-ordered
peaks from each treatment group were compared, with rank based on the mean signal
intensity within each interval of determined open chromatin (Figure 13A). 68% of the
LXRa bound regions from both treatments were restricted to those sites and LXRa
bound regions exhibit high DNA accessibility compared to randomly selected open
chromatin sites (Figure 13B).
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Figure 12: Mapping of chromatin accessibility using FAIRE-seq. Gene loci of
SREBF1, ABCD1 and ABCA1 illustrating the correspondence between LXRa occu-
pancy patterns (LXRa ChIP-seq) and FAIRE-enriched accessible regions (FAIRE-seq)
in vehicle-treated macrophages (Control, blue), T0901317-treated macrophages (T09,
red) and T0901317-treated foam cells (oxLDL + T09, green). Peak intervals of highly
accessible sites are indicated as black bars below the density profile. Constitutive
sites of accessible chromatin are indicated by black arrows and treatment-specific
accessible sites are indicated by red (accessible in T0901317-treated macrophages)
and green (accessible in T0901317-treated foam cells) arrows. LXRa unbound sites
of open chromatin at the SREPF1 and ABCD1 locus are indicated by gray arrows.
Scaling of LXRa data as in figure 2 and 5. FAIRE-seq profiles are processed as
described and are equally scaled to fit the enriched peak intervals. Genomic loca-
tions: SREBF1: chr17:17,728,884-17,745,176. ABCD1: chrX:152,980,867-153,001,989.
ABCA1: chr9:107,688,019-107,841,388. UCSC Genes track is used to indicate RefSeq
validated gene positions.
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Stringent correlation of treatment-dependent LXRa occupancy to FAIRE-seq en-
riched sites revealed that 43% of T0901317-induced LXRa binding in differentiated
THP-1 cells and 76% of LXRa occupied sites in T0901317-treated foam cells are tar-
geted to the 2.2% of the genome defined by regions of open chromatin (Figure 13C).
Thus, the increased accessibility at LXRa binding sites in T0901317-treated foam cells
correlates with the higher number of direct LXRa target genes, compared to T0901317-
treated macrophages. The majority of treatment-dependent LXRa occupancy at open
sites (65% and 84%) occurred in constitutively open chromatin whereas 35% and 16%
occurred at sites that undergo treatment-induced chromatin remodelling for both cell
models respectively. Only a marginal fraction of LXRa sites were located at uniquely
pre-treatment open chromatin sites.
The marked differences between both macrophage treatment models regarding
their association to accessible chromatin were further investigated by visualizing open
chromatin sites at LXRa bound regions. Strikingly, the fraction of LXRa binding sites
that are unique to T0901317-treated macrophages are mainly associated with regions
of close chromatin whereas LXRa binding sites common to both treatment models
or unique to T0901317-treated foam cells showed an equivalently high amount of
co-localized open chromatin (Figure 14A). Together, these results indicate that LXRa
binding coincides both sites of open chromatin and sites where chromatin exists in a
relatively close conformation. Thus, heatmap visualisation indicates that T0901317
induces LXRa binding to inaccessible chromatin in macrophages. Therefore, large
fractions of these binding sites may not be functional due to the lack of associated chro-
matin accessibility that prevents recruitment of co-factors required for transcriptional
regulation of target genes.
Previous studies indicate that the level of regulatory factor occupancy on a given
genomic region is an important determinant of function (Li et al. 2011). To ask whether
LXRa binding to close chromatin reflects a functional mechanism or simply discrimi-
nates weak LXRa binding sites, the significance of LXRa peaks was determined relative
to the chromatin status (Figure 14B). The analysis revealed that on average LXRa
binds with higher affinity to sites of open chromatin compared to its binding affinity to
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Figure 13: Global evaluation of chromatin accessibility on LXRa occupancy
patterns. (A) Matrix of Jaccard similarity coefficients between all FAIRE-enriched
sites and the top 10k FAIRE-enriched sites. The Jaccard index is estimated as the
number of peaks that overlap between two peak files, divided by the union of the
two files. The larger the coefficient, the more similar two datasets are in terms of
overlapping peaks. Shown values are adjusted to percent overlap. (B) Box plot showing
FAIRE-seq mean signals at LXRa binding sites of T0901317-treated macrophages (T09,
red) and T0901317-treated foam cells (T09 + oxLDL , green) compared to random peak
intervals that mimic LXRa peaks (Random). (C) LXRa binding and chromatin acces-
sibility in T0901317-treated macrophages (T09), T0901317-treated foam cells (T09 +
oxLDL) . Percentage of overlapping LXRa binding sites with determined sites of high
accessibility (high FAIRE-enrichment, open) or inaccessible chromatin (low FAIRE en-
richment (closed). Legend: Const. (constitutive) open sites are accessible independent
of treatment or cell model. Induced open sites are accessible after T0901317 treatment.
Induced closed sites are defined as open sites in untreated cells that are inaccessible
after T0901317 treatment. Overlapping sites are defined by an intersection of ≥ 10 bp.
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Figure 14: Global evaluation of chromatin accessibility on LXRa occupancy
patterns (2). (A) Tag enrichments (from figure 4, LXRa ChIP-seq) over all 400 sorted
LXRa binding sites (LXR Peak) is shown along with defined sites of open chromatin
(FAIRE-seq). (B) Aligned dot plot shows LXRa binding sites significance calculated by
MACS at defined FAIRE sites (for definitions see figure 13).
close chromatin. Nevertheless, some strong LXRa binding sites mapped also to inac-
cessible chromatin. Those highly significant binding sites were individually inspected
showing that the binding events were almost exclusively annotated to validated LXRa-
associated genes that are targeted by multiple LXRa binding events as described for
the ABCA1 gene. In the corresponding loci of positively regulated target genes, at least
one LXRa binding interval was situated in open chromatin (Figure 12, ABCA1).
3.5.4 LXRa binding to accessible chromatin positively correlates with dif-
ferential expression of target genes
To further determine the functional effect of LXRa binding depended on different
chromatin states, peak-associated genes (defined by the nearest gene analysis strategy)
that are differentially expressed under ligand treatment were grouped according to
their chromatin status. Strikingly, genes regulated by LXRa binding are less likely to be
differentially expressed if binding is restricted to closed chromatin. The broad majority
of differentially expressed genes are targeted by LXRa binding sites in accessible
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Figure 15: LXRa binding to accessible sites coincides functionality. (A) LXRa
binding to accessible chromatin positively correlates with enhanced up-regulation
of associated LXRa targt genes. The chromatin status at LXRa binding sites is in-
dicated at the x axis. Dots indicate fold-expression changes from T0901317-treated
macrophages (red) and T0901317-treated foam cells (green). (B) Results of de novo
motif discovery and the reported LXRa motif (M00965). (C) Different indicators for
functional transcription factor binding sites are over-represented at LXRa binding
sites in open chromatin. Transcription factor hotspots (TF hotspot) are defined by
≥10 transcription factor binding sites (ENCODE Txn ChIP-seq data, data update:
2011-04-28).
chromatin, indicating that open chromatin is a good predictor of transcription factor
binding events that finally lead to gene expression (Figure 15A and C).
3.5.5 Correlation of motif occurrences relative to the chromatin status
The mode of interaction between LXRa to DNA is believed to depend on the sequence
context. Therefore recognition-motif occurrence at transcription factor binding regions
provides an additional indicator for functional relevance. To investigate whether LXRa
binding events at LXRa consensus motifs correlate with accessible chromatin, the
occurrence of the motif in open and close chromatin was analysed. Therefore, the
motif instances for all defined LXRa binding sites were investigated by de novo motif
search using the MEME suite (Machanick and Bailey 2011). The analysis revealed
that 20% and 26% of the defined LXRa peak intervals stringently contain the sequence
motif highly similar to the published LXRa motif (M00965, centipede.uchicago.edu,
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Figure 15B) from both treatment groups respectively. Similar to the observations from
gene expression, the vast majority of peaks containing the LXRa motif were found in
domains of open chromatin and only five motif containing peaks were determined that
reside in regions of close chromatin (Figure 15C). Again, this shows that most binding
sites with an additional parameter for functional relevance are restricted to regions of
accessible chromatin.
An enhanced trend was observed when determining the presence of the RXRa motif
in addition with RXRa ChIP-seq enrichments from publicly available data (ENCODE
consortium, genome.gov) at LXRa peak intervals (Figure 15C). Because RXRa is an
obligatory partner of LXRa this finding also elucidates that the fraction of LXRa motifs
found by de novo search may be underestimated. De novo motif search centred on
estimated RXRa binding sites with LXRa peak intervals lacking a detectable LXRa
motif did not reveal a specific motif in addition to the RXRa motif. However, this
strongly suggests that a fraction of functional LXRa binding events is independent of
the known consensus sequence. Unfortunately, the relatively low numbers of binding
intervals with these properties challenged the finding of subgroups of variable LXRa
motifs. Further investigations by the use of alternative motif determination strategies
will be necessary to gain a deeper understanding regarding alternative LXRa consensus
sequences.
It was previously shown that only a very small fraction of the genome-wide available
transcription factor response element sequences is occupied by direct factor binding
(Farnham 2009). Therefore, the genome-wide identification of active regulatory regions
by FAIRE remains a promising strategy to specifically investigate motif occurrences at
these functional sites.
3.6 LXRa binds to transcription factor hotspots and is associated
with a set of pioneer factors
Previous, large-scale profiling of the binding patterns from a set of transcription fac-
tors in Drosophila melanogaster revealed strongly overlapping localization patterns,
indicating the presence of transcription factor hotspots (Moorman et al. 2006, Roy
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Figure 16: Co-occurrence of LXRa and other transcription factors. Transcrip-
tion factors strongly overlap with each other in the genome and form transcription
factor hotspots. (A) Representation of LXRa ChIP-seq profiles, profiles of other tran-
scription factors (ENCODE Txn ChIP-seq data, data update: 2011-04-28) and con-
served transcription factor binding motifs (Cons. Motifs, UCSC TFBS Conserved
Track). (B) Tag enrichments (from figure 4, LXRa ChIP-seq) over all 400 sorted
LXRa binding sites (LXR Peak) is shown along with transcription factors binding sites
((ENCODE Txn ChIP-seq data). (C) Over-represented conserved transcription factor
binding sites at sites of LXRa binding to open chromatin.
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et al. 2010). Transcription factor hotspots, also termed highly occupied target (HOT)
regions, correlate with pattern of open chromatin and also exist in the human genome
(Li et al. 2011, Siersbaek et al. 2011). To investigate whether LXRa binding events
are located in highly occupied target regions, binding sites of 148 transcription factors
from multiple human cell lines released by the ENCODE consortium (genome.gov)
were visualized within and around genomic regions of LXRa binding events (Figure
16A and B). Remarkably, this comparison shows that a major fraction of LXRa binding
sites are located in transcription factor hotspots. Especially highly significant LXRa
binding sites that are common to both macrophage treatment models are associated
with regions of broad transcription factor binding site accumulations. Additionally,
these results visually confirm the association of hotspots with defined sites of open
chromatin. Relating to LXRa, the majority of hotspots with a complexity of ten or
more transcription factor binding sites are associated with LXRa occupancy at open
chromatin (Figure 15C). Together, these correlations confirm that LXRa is associated
with other transcription factors that cluster near each other to cooperatively regulate
transcription. The observation that most LXRa binding sites are associated to constitu-
tively accessible regions that are additionally defined by transcription factor hotspots
suggests, that hotspots are stable genomic regions kept open via recruitment of specific
pioneer factors chromatin remodeling complexes, that facilitate binding of additional
transcription factors (Magnani et al. 2011, Voss et al. 2011).
To understand whether LXRa binding is accompanied by the presence of specific
transcription factors that may contribute to the definition of functional regulatory
elements, transcription factor co-occupancy at LXRa binding sites was further inves-
tigated. De novo motif search using LXRa peak intervals revealed the presence of
the specificity protein 1 (SP1) motif a transcription factor directly associated with
accessible and poised chromatin (Biddie et al. 2011). To expand this observation over-
representation analysis of numerous conserved transcription factor motif occurrences
was performed. Therefor, LXRa binding sites associated with accessible and inaccessi-
ble chromatin were used as positive and negative sequence sets, respectively. These
sequences were scanned using available PWMs from the Transfac database (Matys
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et al. 2003). Afterwards, comparing the positive and negative sequence sets assessed
the ratio of enriched transcription factor binding sites along with significance values
for each transcription factor. The analysis revealed the expected over-representation
of the LXR motif. Additionally, several motifs of pioneer factors were associated with
LXRa binding events at open chromatin (Figure 16C). Those include SP1, AP-1, AP-2,
AP-2a and PU-1 (SPI1). These findings suggest, that the determined pioneer factors
may cross-talk with LXRa. In addition to the known pioneer factors, binding sites of
the cell-cycle and apoptosis regulator E2F1 were also significantly overrepresented
near LXRa binding sites in open chromatin. Interestingly, the transcriptional repressor
protein YY1 was identified as the only factor significantly enriched near LXRa binding
sites in close chromatin. Together, these findings revealed novel potential partners of
LXRa that influence factor binding and the functional outcome of LXRa activation.
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4 Discussion
The abundant expression of the LXRa protein in macrophages present in human
atherosclerotic lesions supports the hypothesis that LXRa agonists could have a bene-
ficial effect against development of atherosclerosis (Watanabe et al. 2005, Zhao and
Dahlman-Wright 2010). Therefore, the effects of LXR activation have been studied in
diverse tissue contexts and cell types, and many LXR target genes were determined
using global expression analysis (Joseph et al. 2003). The interpretation of such studies
has been hampered because expression analysis alone cannot differentiate between
direct and indirect targets and does not provide information on the location of regula-
tory elements. Therefore, for gaining a general understanding of the mechanisms of
LXRa-dependent gene regulation it is essential to monitor the genome-wide location of
LXRa to define direct LXRa target genes. To understand the role of LXRa activation in
regulating different sets of genes in macrophages attracted to atherosclerotic plaques
and already transformed cholesterol accumulating macrophage-derived foam cells,
LXRa occupancy and gene expression was determined and correlated in T0901317-
treated macrophages or foam cells treated with T0901317 as compared to untreated
macrophages.
4.1 Properties of LXRa cistromes
Using ChIP-seq analysis about 249 and 215 LXRa binding sites with a high degree of
confidence were identified in T0901317-treated macrophages and foam cells, respec-
tively. LXRa cistromes in these cells are largely distinct, although 16% of the binding
locations are shared between the macrophage models. The marked differences of LXRa
cistromes are similar to the distinct cell-type specific binding occurrences of other
nuclear receptors such as glucocorticoid receptor (GR) and peroxisome proliferator
activator receptor gamma (PPARg) (John et al. 2008, Lefterova et al. 2010). This
elucidates that oxLDL stimulation and subsequent foam cell development is sufficient
to induce large changes in transcription factor DNA binding locations and thereby
targeting different gene sets.
46
Until recently, the study of LXRa action was limited to promoters of a few well-
characterized target genes. However, global analysis revealed that the majority of the
identified LXRa binding sites are located in distal intergenic regions or introns whereas
fewer sites are localized to proximal promoter regions (11%). The high distribution of
binding sites within intergenic and intron regions is consistent with similar reports for
other nuclear receptors, including PPARg (Lefterova et al. 2008), estrogen receptor a
(Carroll et al. 2005), androgen receptor (Bolton et al. 2007) and others (Chong et al.
2010, Tang et al. 2011). This finding elucidates that LXRs frequently act as long-range
enhancers rather than classic promoter-associated transcription factors.
4.2 Positive regulation of known and novel LXRa target genes
The genomic intervals bound by LXRa in the vicinity of T0901317-responsive genes
constitute a rich starting set for the study of LXRa-dependent gene regulation. While
LXRa binding to DNA can in principle activate and repress gene expression, combining
LXRa occupancy data with measurements of gene expression response showed that
LXRa mainly functions as a transcriptional activator. A basic subset of direct LXRa
target genes in both macrophage models includes the established LXR target genes
ABCA1, ABCG1 and LXRa. ABCA1 and ABCG1 are cholesteror transporters and highly
induced genes that are central to the antiatherogenic effects of LXR ligands (Wang
and Tall 2003). Deficiency of ABCA1 and ABCG1 promotes foam cell accumulation
and enhances atherosclerotic lesion development in mice (Yvan-Charvet et al. 2007).
Strikingly, these genes are associated with multiple LXRa binding sites, suggesting
that these regulatory elements are coevolving to balance target gene expression. Most
of the binding sites identified in these classical and well-studied LXR-responsive genes
are novel. Beside the proximal LXR response element in the promoter of ABCA1
(Costet et al. 2000) and two distal LXR occupied enhancers (Shen et al. 2011) five
additional sites of LXRa binding were identified. Similarly, two previously unknown
LXRa binding sites were identified in the second intron of ABCG1 that coexist with the
previously described promoter proximal LXR response elements (Kennedy et al. 2001,
Shen et al. 2011). Previously undetermined LXR binding sites were also identified for
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the two known LXR target genes SCD and MYLIP (Zelcer et al. 2009b). Identification of
those novel binding sites will enable further investigations of those important factors.
Correlation of gene expression and LXRa binding also revealed undetermined
LXRa target genes commonly regulated in both T0901317-treated macrophage models
including ABCD1, NRIP1 and TNFRSF21. ABCD1 encodes a peroxisomal membrane
protein which is essential for catabolism of very long chain fatty acids (Weinhofer et al.
2002). Therefore, ABCD1 represents an important novel target to reduce cellular fatty
acid levels. The co-repressor NRIP1 is an interaction partner of ligand-activated LXRs
(Jakobsson et al. 2007a). NRIP1 and LXR can partner to form distinct activator or
repressor complexes to either regulate lipid generation or reduce glucose production
(Herzog et al. 2007). TNFRSF21 belongs to the death receptor subfamily of the
tumor necrosis factor receptor superfamily (TNFRs) (Pan et al. 1998) and activates
a widespread caspase-dependent self-destruction program (Nikolaev et al. 2009). It
was observerd that a subset of oxysterols induce apoptosis via unknown acceptor
proteins (Shibata and Glass 2009). Expression of TNFRSF21 might therefore represent
a possible cellular reaction to oxysterols or LXR ligands in general, which induce
apoptosis. Excessive apoptosis is thought to promote atherosclerosis. Paradoxically,
mice with deficiency of macrophage specific anti-apoptotic factors are protected from
developing atherosclerosis presumably because of increased apoptosis of macrophages
during the early stages of plaque development (Im and Osborne 2011).
4.3 Multiple effects of LXR agonists in macrophages and foam cells
Comparison of direct LXRa target genes in T0901317-exposed macrophages and foam
cells revealed the effect of hyperstimulation of fatty acid synthesis pathways in
macrophages as previously observed (Chisholm et al. 2003). Contrary, in T0901317-
treated foam cells these effects were attenuated, presumably by cholesterol-induced
suppression of SREBP pathways (Horton et al. 2002). LXRs and SREBPs bind to and
activate many of the same genes involved in de novo fatty acid biosynthesis (Shibata
and Glass 2009). Interestingly, LXRa binding to those genes was maintained in foam
cells suggesting that suppression of SREBP pathways would be sufficient to reduce
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fatty acid accumulation. This highlights that promising novel LXR agonists should
separate beneficial effects from the stimulation of fatty acid synthesis via attenuation
of SREBP activation. However, understanding how these opposing functions of LXR
activators are regulated is an important area for future investigation. Moreover, fur-
ther single-gene investigations of LXRa targets that are differentially induced in both
macrophage models are required to gain a more comprehensive picture of LXRa actions
in different cellular conditions.
4.4 LXRa-dependent repression of pro-inflammatory genes
Although most direct LXRa target genes are transcriptionally activated, four genes
were identified that are down-regulated upon LXRa activation. Recent studies have
revealed that the activation of LXRs in macrophages inhibits toll like receptor (TLR)-
inducible inflammatory genes, such as IL-1b and MCP-1 (Joseph et al. 2003). In
accordance inflammatory gene clusters were significantly down-regulated in T0901317-
treated foam cells. It was shown that repression of those pro-inflammatory genes
is correlated with promoter proximal binding of LXR in mice (Ghisletti et al. 2007,
Huang et al. 2009b). Contrary, in human macrophages or foam cells direct LXRa
binding was not detected at inflammatory gene loci. One explanation is that LXRa-
mediated repression involves long-range cis-interactions or tethering of LXRa to other
factors as initially proposed (Li and Glass 2004). However, one might also expect such
interactions would become fixed with cross-linking, and would appear as binding sites
in ChIP-seq profiles (Reddy et al. 2009).
Interestingly, CD14 is down-regulated and LXRa bound exclusively in foam cells,
underscoring that this gene is strictly regulated by LXRa. CD14 acts as a co-receptor
along with TLRs and is required for TLR4-dependent activation of inflammatory genes
by interfering with nuclear factor-kB (NF-kB) pathways (Triantafilou and Triantafilou
2002, Ghisletti et al. 2007). Together, these observations suggest that suppression of
CD14 as an upstream activator of inflammatory genes represents a meaningful expla-
nation of indirect LXRa-dependent anti-inflammatory effects in human macrophages
upon oxLDL-induced inflammatory response (Hao et al. 2010).
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4.5 Beyond direct target gene regulation
LXRa cistromes in conjunction with transcriptional profiling revealed novel binding
regions and identified or substantiated the LXR-responsiveness of a number of genes
involved in critical processes. However, beside its direct regulation of target genes
LXRa up-regulates a number of distinct transcription factors in T0901317-treated
macrophage and foam cells. It was determined that these factors are connected to a
vast number of differentially expressed genes. It is therefore interesting to elucidate
the functions of these factors to gain insights into the complex regulatory network
targeted by LXRa.
Defined LXRa target genes in T0901317-treated macrophages include stringent
regulation of the three transcription factors SREBF1, nuclear receptor interacting
protein 1 (NRIP1, RIP140) and the nuclear receptor retinoic acid receptor alpha (RARa,
NR1B1). As already mentioned, SREBF1 is a well-studied direct LXRa target that
plays crucial role in lipid homoeostasis (Repa et al. 2000, Horton et al. 2002). NRIP1
was considered as LXR co-repressor but its direct regulation by LXRa binding remained
unexplored (Herzog et al. 2007, Jakobsson et al. 2007b). The nuclear receptor RARa
was only recently identified as occupied and regulated by LXRa binding (Rebe et al.
2009). Many differentially expressed genes contain RARa motifs in their promoter
regions. Therefore, the cross-talk of LXRa and RARa represents an interesting issue
that requires further investigations.
In T0901317-treated foam cells LXRa directly regulates five transcription factors
including max-binding protein (MNT) and jun proto-oncogene (JUN) as well as NRIP1
that showed regulation in both cell models. These factors were not yet described
as direct LXRa target genes. Widespread interactions were reported for the MNT
transcription factor, a player in the MAX-interaction network (Hurlin and Huang
2006). However, its role in macrophages and the development of atherosclerosis is
unclear. The JUN gene encodes a protein (c-Jun) that, together with the FBJ murine
osteosarcoma viral oncogene homolog (FOS), forms the transcription factor activator
protein 1 (AP-1). AP-1 plays a critical role in many signal transduction pathways and
was recently implicated in the maintenance of open chromatin to direct glucocorticoid
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receptor binding (Biddie et al. 2011). Moreover, the functional connection of AP-1
and LXRs was recently reported (Shen et al. 2011). AP-1 binding sites are also over-
represented in regions of open chromatin that are bound by LXRa, indicating that AP-1
is a critical pioneer factor to bookmark functional regulatory elements. Interestingly,
LXR agonists induced the binding of AP-1 to its recognition sequences in several
gene promoters which contain AP-1 binding sites, indicating that AP-1 might also
play an important roles in co-regulating genes such as ApoE and ABCA1 (Huwait
et al. 2011, Shen et al. 2011). Moreover, c-Jun is involved in c-Jun N-terminal kinase
(JNK) pathways connected to LXR agonists-induced expression of target genes in
macrophages albeit the exact mechanism through which LXR agonists activate c-Jun
remained unexplored (Huwait et al. 2011). It was suspected that c-Jun-associated
pathways are regulated through non-genomic effects (Schmuth et al. 2004). The present
study suggests for the fist time that JUN is directly LXRa up-regulated by a distal
LXR response element. Although additional validation experiments are necessary, this
finding possibly explains the molecular mechanism how LXR agonists activate several
components of the JNK pathway.
The transcriptional activation of several transcription factors by LXRa illustrates
that the action of nuclear receptors in the regulation of gene transcription is complex
with control by intracellular signaling pathways of the receptors themselves, co-factors
recruited by them or other transcription factors that are required for the maximal
expression of downstream genes (Huwait et al. 2011, Burns and Vanden Heuvel 2007).
Therefore, directly targeted transcription factors are likely to be critical components
of the LXRa transcriptional program, since in principle they can crosstalk with each
other and regulate other cascades of genes that finally define the cellular response to
T0901317 and oxLDL stimulations in macrophages.
4.6 Agonists influence LXR DNA binding
The influences of agonist binding on DNA occupancy for nuclear receptors in vivo in
general and for those where endogenous metabolically derived compounds function as
agonists in particular is complicated and not clearly understood (Chong et al. 2010).
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The differential distribution of LXRa binding events in macrophages and foam cells
suggests that agonists influence the specificity of LXRa binding. Remarkably, in
contrast to T0901317-treated cells, in untreated THP-1-derived macrophages, LXRa
DNA binding was globally undetected. Contrary, the model that LXR is bound to
response elements in the absence of a ligand dominates the scientific literature (Li
and Glass 2004, Zhu and Li 2009, Zhao and Dahlman-Wright 2010, Viennois et al.
2011). Hu and co-workers using ChIP-PCR initially showed that LXRa bound response
elements are constitutively occupied. Ligand activation triggers the release of the
co-repressor N-CoR leading to gene expression of occupied promoters (Hu et al. 2003).
However according to recent studies, there is evidence for strictly agonist-dependent
changes in binding of LXR to DNA in cultured cell models and primary cells determined
by ChIP assays. Johansson and co-workers showed promoter specific ligand-dependent
LXR recruitment in HepG2 and THP-1 cells (Jakobsson et al. 2009). Several other
studies showed ligand-induced binding at a number of LXR responsive genes that are
activated or repressed upon LXR ligand treatment (Ghisletti et al. 2007, Kim et al.
2009, Venteclef et al. 2010).
The absence of LXRa binding in uninduced macrophages is in accordance with
the low amount of measured LXRa protein levels and thus indicates that the protein
level is a critical parameter for subsequent gene regulatory action of LXR. Together,
the genome-wide analysis of LXRa cistromes in macrophage suggests that ligand-
dependent DNA binding is a general principle to activate gene expression of LXRa and
concomitant binding to regulatory regions of LXRa target genes.
4.7 Chromatin accessibility and co-localized transcription factors
Several lines of evidence indicate that sites of open chromatin, defined by FAIRE
(Giresi et al. 2007, Giresi and Lieb 2009), reliably identify active regulatory elements
because of the following observations that are similar to DNase I hypersensitive sites
detection assays (Boyle et al. 2008). It was shown that regions of open chromatin
contain widespread and overlapping patterns of determined transcription factor bind-
ing sites (Li et al. 2011) and most enriched FAIRE regions were found near known
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regulatory active transcription start sites (Gaulton et al. 2010). FAIRE-seq analysis of
the chromatin landscape in macrophages at LXRa binding sites confirmed that acces-
sible chromatin is highly correlative with transcriptional regulation of nearby genes.
Moreover LXRa occupied regions in open chromatin are accompanied by numerous
other factors, which underlines that these regions are functional enhancers (Chen et al.
2008, Roy et al. 2010, Moorman et al. 2006).
Estimation of the genome-wide chromatin accessibility in macrophages is in accor-
dance with previous observations (John et al. 2011, Bernstein et al. 2010, Boyle et al.
2008, Song et al. 2011) and revealed that ~2% of the genome is depleted in nucleosomes
and highly accessible. As recognized before (Hurtado et al. 2011), the small overlap of
genome-wide treatment specific sites of open chromatin suggests that the vast majority
of localized reorganization events are not stable but in fact represent a highly dynamic
process. Interestingly, only 43% of LXRa binding sites induced by the synthetic lig-
and alone are associated to open chromatin whereas 76% of LXRa binding sites of
oxLDL-triggered T0901317-treated foam cells matched to those regions. The major
fraction of LXRa binding sites at inaccessible chromatin represent binding sites unique
for T0901317-treated macrophages. Together with gene expression correlations, this
observation indicates that those LXRa binding sites are non-functional and putatively
serve as a reservoir to maintain an optimum amount of available transcription factor
analogous to other biological buffering systems (MacQuarrie et al. 2011). However, the
potential biological role of many of the sites remains largely undetermined (Farnham
2009). Together, this indicates also that artificial activation of LXRa by synthetic
ligands is responsible for high amounts of induced non-functional binding. Therefore,
the genome-wide analysis of chromatin accessibility is a valuable tool to determine
functional LXRa binding events.
Most transcriptional regulators recognize short consensus sequences that occur
frequently near most of the genes (Wunderlich and Mirny 2009). The underlying mech-
anism whereby LXRa selects a limited number of binding sites from a huge number of
potential recognition sequences remains elusive. Therefore, the selective binding to a
subset of sites in a given cellular environment mediating transcriptional regulation,
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begs the question of how binding is orchestrated. Nuclear receptors have been shown
to bind preset regions of accessible chromatin (Eeckhoute et al. 2006, Eeckhoute et al.
2009, John et al. 2008, Lefterova et al. 2010). This contradicts the activity of nuclear
receptors as pioneer factors and rather suggests that nuclear receptors act coopera-
tively through cooperation with other factors to mediate transcriptional regulation
(Biddie et al. 2010).
Given that LXRa to a large extend occupy pre-existing accessible sites in the genome
that are accompanied by other factors, it will be important to understand the role of
regulatory factors that initiate and maintain chromatin accessibility. The success-
ful identification of several potentially cooperative transcription factors and pioneer
factors at LXRa binding sites in open chromatin therefore represents a meaningful
starting set for further investigations. Pioneer factors are defined as a specific class of
transcription factors that are required and sufficient to trigger enhancer competency
(Magnani et al. 2011). Genome-wide cistromes of LXRb in human keratinocytes and
mouse macrophages already showed co-localization of AP-1 and PU-1 binding respec-
tively (Shen et al. 2011, Heinz et al. 2010). It was shown that PU.1 binding functions
as a marker that defines the set of potential cis-regulatory elements through repro-
gramming the chromatin landscape that will subsequently be bound by LXRb (Heinz
et al. 2010). Similarly, it was shown that the transcription factor AP-1 maintains
baseline chromatin accessibility facilitating glucocorticoid receptor (GR) recruitment
(Biddie et al. 2011). Thus, this findings suggest that AP-1 is a major partner for pro-
ductive LXRa-chromatin regulation and LXRa-regulated transcription. Interestingly,
LXR binding to close chromatin is accompanied by the presence of the transcriptional
repressor protein YY1 (“yin-yang”) motif. Understanding the repertoire of LXRa inter-
actions with these factors and cofactors will clearly be important for elucidating novel
mechanisms in the pathophysiological processes of LXR action.
4.8 Challenges in genome-wide nuclear receptor research
A major difficulty faced by transcription factor ChIP-seq studies is the technical
problem of having to assign binding sites with specific gene promoters (Dietz and
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Carroll 2008). Another challenge is to understand gene expression data from cells
exposed to specific nuclear receptor agonists. Genome-wide expression profiling
shows that T0901317 exposure up-regulates and down-regulates hundreds of genes
in macrophages. In contrast, nearest gene analysis revealed a distinct set of only 52
genes in both treatment models that exhibit both, LXRa binding and differential gene
expression regulation upon ligand induction. A naïve interpretation of this discrepancy
is that the majority of genes associated with LXRa binding regions are apparently
T0901317-unresponsive. The observed phenomenon is common to several transcription
factor ChIP-seq studies (Bolton et al. 2007, Lefterova et al. 2010, Farnham 2009) and
therefore highlights the complexity of transcription factor binding and gene regulation.
The importance of indirect LXRa effects through regulation of other transcription
factors was already delineated. However, several additional reasons could account
for the apparent discrepancy regarding the connection of binding events and gene
expression regulation.
It is important to consider the effect of pharmacological LXR activation on gene
expression changes. T0901317 is a potent activator of LXRs and LXRa effects are
enhanced upon auto-up-regulation. However, this compound is not completely selective
for LXR since it is able to activate PXR (Mitro et al. 2007) and FXR (Houck et al.
2004) and inhibits RAR-related orphan receptors alpha (RORa) and RORg (Kumar
et al. 2010). Similarly, the oxLDL-derived oxysterols regulate diverse other nuclear
receptors including PPARg (Shibata and Glass 2009). Therefore, gene expression
changes triggered by endogenous or synthetic ligands may exter some aspecific effects.
It is therefore crucial for future work to incorporate LXR knock-down expression
profiles into correlation analyses.
Another important technical challenge represent the transcription factor binding
site annotation. There is no consensus as to how far a transcription factor-binding
region should be in order to be considered a putative cis-acting regulatory domain
for a given gene (Jariwala et al. 2007). Although binding sites occur in abundance
distal to promoters in terms of the linear genomic distance, chromatin is organized
into higher-order structures to form chromosomes that are non-randomly positioned in
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the three-dimensional nucleus (Takizawa et al. 2008, Biddie et al. 2010). Distal regula-
tory elements might therefore associate with promoters of responsive genes or enable
recruitment of cofactors and the basal transcriptional machinery to transcriptionally
active nuclear compartments. For example, in a ligand-dependent manner, LXR facili-
tates physical interactions between LXR-bound enhancer regions and the promoters
of ABCG1 in Huh7 cells to mediate transcription (Jakobsson et al. 2009). However,
genome-wide determination of long-range interactions between regulatory elements
using chromatin interaction analysis by paired-end tag sequencing (ChIA-PET) (Li
et al. 2010) or Hi-C (van Berkum et al. 2010) approaches are difficult to established.
Therefore, it is not yet possible to reliably connect binding events to the array of genes
they regulate. Distal LXRa occupied regions may still regulate distant annotated genes
on the same or even other chromosomes (Fullwood et al. 2009), or they may regulate
nearby unannotated transcripts. Some observations indeed suggest that gene clusters
may be regulated by distal LXRa binding events. It was determined that some LXRa
binding events are surrounded by widespread clusters of differentially expressed genes
that are hundreds of kilobases away and were therefore not annotated to the LXRa
binding site. Interestingly, many distal genes and LXRa binding sites were found to be
CTCF bound. CTCF has been proposed to partition the genome into functional blocks
and mediate long-range interactions (Splinter et al. 2006, Phillips and Corces 2009,
Hou et al. 2010). Correlation of publicly available CTCF ChIP-seq data with LXRa
binding and gene expression changes indicates the possibility of long-range interaction
by DNA looping (Figure 17). However, CTCF binding alone is not able to accurately
predict functional long-range interactions as CTCF-bound sites are not exclusively
located in the centre of interaction complexes (Handoko et al. 2011, Bau et al. 2011).
Clearly, our understanding of the communication between LXRa binding at enhancers
and the promoters of target genes requires future work, including the development of
comprehensive bioinformatics strategies for binding site annotation.
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Figure 17: LXRa binding in a cluster of transcriptionally regulated genes.
(Top) Possible chromatin looping interactions between a differentially expressed gene
cluster and a distal regulatory element occupied by LXRa (arrow) in T0901317-treated
foam cells. The putative loops (blue) are placed over the one-dimensional representation
of a selected genomic region (chr5:139,359,560-140,170,670) and connect intervals
occupied by CTCF (ChIP-seq profiles from Broad/MGH ENCODE group in K562
(violet), HeLa-S3 (blue) and HepG2 (magenta) cells). FAIRE-seq heatmap (yellow
to red) of T0901317-treated foam cells. The RefSeq genes track is used to indicate
gene positions (grey). Regulated genes are shown as black bars and the fold-change is
indicated. LXRa ChIP-seq profile of T0901317-treated foam cells (green). (Bottom)
Model for higher-order chromatin folding of actively transcribed genomic regions.
Actively expressed genes (green) dynamically associate with transcription factories or
globule cores (light red) whereas inactive genes (red) are located more distal. Many
domains that exist as loops are connected by CTCF (dark green) and chromatin at the




The combination of LXRa ChIP-seq, FAIRE-seq and global gene expression analysis
enabled insights into LXRa-dependent regulation of target genes and molecular mech-
anisms of LXRa activation. However, integrative analysis revealed that correlation
of gene regulation and nuclear receptors DNA binding is highly complex. LXRa does
not act individually to regulate particular genes but cooperates with other factors
and activates broad regulatory networks via interaction with several transcription
factors. Therefore, to understand the effect of LXRa on different metabolic pathways
and their complex interactions it is necessary to develop systems biology approaches.
Ideally, these approaches must incorporate many associated transcription factors.
Secondly, ChIP-seq procedures provides many new hypotheses for follow-up in depth
functional studies of distinct genes. The detailed characterization of the T0901317
response in macrophages and macrophage-derived foam cells presented here may help
further our understanding of treating atherosclerosis and other diseases by interfering




Human THP-1 monocytic-like leukemia cells (ATCC) were cultured in RPMI medium
supplemented with 10% fetal bovine serum (FBS, Biochrom), at 37°C in a humidified
10% CO2 atmosphere. The cells were seeded in T-150 flasks at a density of 2100 cells/ml.
Cells were split twice times per week and re-seeded in new flasks in order to prevent
crowding. The medium was renewed every 3-4 days. Approximately 1.2*107 cells were
differentiated into a macrophage-like phenotype by incubation with 0.01 nM phorbol
myristate acetate (PMA, Sigmar Aldrich) for 48 hours.
Human primary macrophages were isolated from buffy coats donated by healthy
volunteers and kindly provided by the GRC Blood Donor Service East non-profit
Ltd. Berlin. Peripheral blood mononuclear cells (PBMC) were isolated by density
centrifugation with Ficoll-Paque (GE Healthcare). Monocyte enrichment from PBMC
was obtained using MACS Monocyte Isolation Kit II and MACS LS columns (Miltenyi
Biotec) yielding >95% purity. For differentiation 5105 cells/ml were plated in RPMI
164 medium supplemented with 10% human AB serum (First Link UK Ltd.) in T-150
flasks and incubated for 7 days at 37°C in a humidified 10% CO2 atmosphere.
THP-1 cells and primary macrophages were treated either with 0.01% DMSO
(vehicle control) or 1 µM T0901317 (Sigma-Aldrich) for 24 hours or with 100 µg/ml
oxidized low-density lipoprotein (oxLDL, Autogen Bioclear) for 48 hours to induce foam
cell formation and subsequently with 1 µM T0901317 for 48 hours.
5.2 Chromatin Immunoprecipitation (ChIP)
ChIP was carried out using the Transcription Factor ChIP kit (Diagenode, Denville,
NJ, kch-redTBP-012).
5.2.1 Cross-linking of chromatin, harvest, and storage
Medium was removed from T-150 flasks and the 1.2*107 cells were washed twice
with PBS and incubated with 9.9 ml freshly prepared cross-linking buffer (3 vol. 37%
59
formaldehyde (Sigma-Aldrich, Steinheim, F8775), 7 vol. Buffer A and 100 vol. PBS) for
10 minutes at room temperature with gentle agitation. To stop cross-linking, 990 µl
1.25 M glycine was added and cells were incubated for 5 minutes with gentle agitation.
Subsequently, the liquid was completely aspired from T-150 flasks and cells were
washed twice with approximately 5 ml of ice-cold PBS. Then, 1.5 ml ice-cold Buffer B
was added. Cells were scraped from the culture flask and transferred to an appropriate
tube on ice. After centrifugation (5 minutes at 4°C and 500g) the supernatant was
removed and 5 ml ice-cold Buffer C was added to the pellet to lyse the cells. The pellet
was resuspended by pipetting up and down several times and incubated for 10 minutes
on ice. After incubation the material was spun (5 minutes at 4°C and 500g), the
supernatant was discarded and cells were resuspended with 624 µl freshly prepared
Buffer D+P.I. (600µl Buffer D and 24 µl 25x Protease Inhibitor Mix) per 1.2*107 cells.
Cells were stored at -80°C
5.2.2 Sonication and assessment of chromatin fragmentation
After storage over night at -80°C the lysate was aliquoted to 240 µl into 1.5 ml protein
low bind tubes (Protein LoBind, Eppendorf) and sonicated for at least 45 minutes
in a 4°C water bath using the Diagenode Bioruptor (UCD-200, Diagenode, Denville,
NJ) set to pulse on high for 30 seconds followed by 30 seconds of rest. To clear the
lysate of cellular debris samples were spun (10 minutes at 14000g and 4°C) and
the supernatant was transferred to new tubes and stored at -80°C. To test shearing
efficacy and fragment sizes, 2.5 µl of sonicated material was analysed by agarose gel
electrophoresis. Therefore, 7.5 µl Buffer F and 0.2 ml 5 M NaCl was added to the test
samples and reverse cross-linking was performed for 16 hours at 65°C using a PCR
cycler. DNA was finally purified using the MinElute PCR purification kit (Qiagen,
Hilden) and eluted with 16 µl water. Eight µl DNA were mixed with 2µl loading buffer
and subsequently analysed on an 1.2% agarose gel (e.g. 0.48mg agarose, 40ml 0.5x TBE
and 1µl 20mg/ml EtBr). Chromatin was subjected to chromatin immunoprecipitation
after DNA was sheared to an average fragment size of 100 - 600 bp. Further rounds
of sonication were performed when needed to ensure that the majority of chromatin
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fragments were in the appropriate size range.
5.2.3 Immunoprecipitation
Immunoprecipitation was prepared on ice in 1.5 ml protein low bind tubes using 12
µl 15% BSA, 20 µl P.I, 8 µl antibody (1 µg/µl), 60 µl prepared agarose beads, 60 µl
fragmented chromatin (adjusted to 350 ng/µl DNA) and 320 µl water to a final volume
of 540 ml. The following antibodies were used: anti-LXRa (1 µg/µl, ab 41902, Abcam)
and mouse IgG (kch-819-015, Diagenode) was used as a negative control antibody.
The prepared immunoprecipitation mix was incubated on a rotating wheel at 4°C
over night. After incubation, beads were spun down (2 minutes at 500g and 4°C)
and the supernatants were gently removed. Beads were washed twice with washing
Buffer 1, once with washing Buffer 2, once with washing Buffer 3 and twice with
washing Buffer 4. For each washing step 700 µl ice-cold wash buffer was added to
the beads and incubation was carried out for 5 minutes on a rotating wheel at 8°C.
Afterwards, beads were spun down (2 minutes at 500g and 4°C) and the supernatants
were gently removed. To elute the DNA, 800 µl room temperature Buffer F was added
and the samples were incubated for 20 minutes at room temperature on a rotating
wheel. Afterwards, beads were spun down (2 minutes at 500g and room temperature)
and supernatants were transferred into 1.5 ml DNA low bind tubes (DNA LoBind,
Eppendorf).
5.2.4 Crosslink reversal, DNA purification and quantification
For de-crosslinking 32 µl 5 M NaCl was added to each sample and samples were heated
at 65°C and 600 rpm over night using a thermo shaker (TS-100, Biolabo Scientific
Instruments). Afterwards, samples were cooled down to room temperature and DNA
was purified using the MinElute PCR purification kit (Qiagen, Hilden) and eluted with
30 µl water. DNA fragments were quantified using the PicoGreen assay (Quant-iT
PicoGreen dsDNA Kit, Invitrogen) and a NanoDrop 3300 fluorospectrometer (Thermo
Scientific). The PicoGreen assay kit uses an ultrasensitive fluorescent nucleic acid stain
for quantitating double-stranded DNA in solution. Therefore, 0.5 µl 200x PicoGreen
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was dissolved in 95 µl 1x TE buffer and 1.5 µl PicoGreen working solution was added
to 1.5 µl precipitated DNA. A standard curve was constructed by a dilution series
of standard lambda phage DNA to calculate the double stranded DNA content of
immunoprecipitated DNA. During the whole procedure, all samples were protected
from light.
5.2.5 ChIP-sequencing
Sample preparation and sequencing was performed by the in house NGS Sequencing
Core facility at the Max Planck Institute for Molecular Genetics. Library preparation
with 10-15 ng of LXRa-ChIP-DNA and IgG-ChIP-DNA was carried out by the use of
the ChIP-Seq Sample Prep Kit (Illumina). Short reads of 36 bp were produced from
the Illumina Genome Analyzer IIx.
5.3 ChIP-seq data analysis
5.3.1 Databases
The human genome February 2009 assembly (GRCh37/hg19) was used as reference
database. All loci are given as hg19 coordinates.
5.3.2 Mapping of sequence data
Unfiltered 36bp sequence reads were uniquely mapped to the human genome using
Bowtie (Langmead et al. 2009) allowing for two mismatches along each tag.
5.3.3 Generation of tag signal profiles
25bp resolution LXRa binding profiles were generated genome-wide using the MACS
tool (Zhang et al. 2008) with the option –wig. Resulting wiggle files (.wig) were
converted to the bigWig format using the program wigToBigWig (Kent et al. 2010).
Normalized signal profiles were generated using makeUCSCfile using the Hyperge-
ometric Optimization of Motif EnRichment (HOMER) software (Heinz et al. 2010).
Resulting bedGraph files (.bg) were converted to the bigWig format using the program
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bedGraphToBigWig (Kent et al. 2010). BigWig files were uploaded to a webserver and
visualized as custome track in the UCSC Genome Browser (Karolchik et al. 2011).
5.3.4 Peak interval determination
Peak identification was performed using the model based-analysis of ChIP-seq algo-
rithm (MACS, Zhang et al. 2008) with aligned sequencing tags in BED format from
LXRa-ChIP and IgG-ChIP experiments. The MACS version 1.0.1 was accessed via
Galaxy (main.g2.bx.psu.edu). The following peak calling parameters were used: p-
value cut-off = 10-5, effective genome size = 2.79, bandwidth = 300 and mfold = 5.
Additionally, three levels (1 kb, 5 kb, 10 kb) of regions around the peak regions were
used to calculate the maximum lambda as local lambda. To estimate the false discovery
rate (FDR) for each peak interval the traditional default method was used. The method
considers the peak location, 1 kb, 5 kb, and 10 kb regions in the control data to calculate
local bias.
5.3.5 Assessment of determined peaks
Initially, a total of 3,779 and 16,013 binding regions were identified in ChIP-seq data of
TO901317-treated macrophages and foam cells respectively. Contrary to expectations
from sequencing depth and visual inspections of ChIP-seq profiles, 6,446 peaks were
determined in data from untreated cells (Figure 19A, left). Therefore, MACS-derived
peak significances were analysed showing highly significant peaks under treatment and
comparably low peak significances in the control set. However, the median significances
of all peaks were similar between treatment groups and most peaks had significances
close to the defined p-value cut-off (Figure 18A and B). To further understand how
the peak interval determinations correspond with actual visible peaks and with likely
LXRa binding, genome regions were manually inspected as suggested by Rye and co-
workers (Rye et al. 2010). The analysis confirmed previous observations. Determined
peaks from untreated cells are not distinct from background (Figure 18C, Control) and
some visually observed peaks were not determined due to corresponding enrichments
of control data (Figure 18C, +).
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By visual determination treatment-derived peaks were likely true positive but
co-treatment-derived peaks seem to accumulate in regions with higher background
indicating false positive binding regions (Figure 18C, #). Furthermore, sets of both
treatments suffered subsequent amounts of weak enrichments that fall into the peak
definition (Figure 18C, *). Additionally, defined peaks with strong enrichments and
high significances were observed that also showed strong tag accumulation in control
date (Figure 18C, right box) and are therefore unlikely to represent true binding sites
(Pickrell et al. 2011). Collectively, the determined peak numbers seemed overestimated.
The presence of large fractions of false positive peak intervals abolished the possibility
of ranking the peaks by decreasing confidence levels either according to coverage by
sequencing reads or according to statistical scores provided by MACS as described
(Rozowsky et al. 2009). Additionally, any downstream analysis with unfiltered peak
interval sets was hugely affected by false positive intervals making feature correlations
impossible. These observations make clear that finding the true binding sites in the
tag profiles of LXRa data sets is not trivial and different issues must be considered to
gain a high-stringency peak set with a maximal amount of true positive peak.
5.3.6 Peak filtering with variable control data
To determine a more stringent peak set the reproducibility of peaks was assessed by
peak calling with LXRa data using three biological replicates of IgG control data sets.
Therefore, peak calling was carried out individually and overlapping peak intervals
were determined that represent a stringent peak set. Estimated peak numbers showed
up to 2.4 fold control-dependent variations and an extreme reduction of filtered peak
number was observed for both treatment conditions with 260 and 1375 peaks in ChIP-
seq data of TO901317-treated macrophages and foam cells respectively (Figure 19A
right). The filtered interval sets showed increased significance indicating the successful
exclusion of false positive peaks (Figure 19B).
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Figure 18: Inspection of determined LXRa peaks. (A) Box plot showing the
distributions of ChIP-Seq peak interval significances (-10*Log10(p-value)) deter-
mined by MACS from vehicle-treated macrophages (Control, blue), T0901317-treated
macrophages (T09, red) and T0901317-treated foam cells (T09 + oxLDL, green) and
significances of peaks that inersect between the data sets. (B) Manhattan plot of peak
interval significances relative to interval positions over the genome from T0901317-
treated macrophages. (C) LXRa ChIP-seq and IgG ChIP-seq profiles and determined
peak intervals (black boxes) show peak intervals with low enrichments (# and *), not
deterimned peaks due to corresponding enrichments of control data (+) and determined
peaks with corresponding enrichments of control data (right).
65
Figure 19: Peak filtering strategy. (A) Left: Venn diagrams showing intersection of
MACS-determined LXRa peaks from vehicle-treated macrophages (blue), T0901317-
treated macrophages (red) and T0901317-treated foam cells (green). Right: MACS-
determined peaks using three biological replicates of IgG control data were intersected
(filtered). (B) Filtered peaks show higher MACS-derived significance compared to
unfilterd peaks (unfiltered). (C) Heat map visualisation and clustering-assisted sub-
filtering of LXRa peak intervals. (D) Heat map visualisation of common and unique
LXRa binding sites. Profiles of foam cell unique LXRa peaks show strong enrichments
of corresponding IgG-derived and T0901317-derived tags over LXRa binding sites (*)
and low tag enrichments (#).
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5.3.7 Peak filtering by the use of k-means clustering
The tag distributions of derived peak sets were individually subjected to k-means
clustering (Heintzman et al. 2009) to organize the identified peaks presenting similar
read densities within a 2 kb window. Clustering was performed using SeqMINER (Ye
et al. 2011). Four clusters were determined to annotate peaks according to enrichment.
The observed clusters elucidate different LXRa binding patterns and show sub-groups
of sites with different binding affinities (Figure19C, Cluster I-IV and VII). Importantly,
clustering allowed exclusion of some peaks with very broad enrichments and sub-
clustering of tags from oxLDL-treated cells enabled discrimination of low enriched
peak intervals (Figure 19C). Comparison of both peak sets revealed that the majority
(93%) of genomic binding sites were unique for each treatment. To test whether tag
enrichment corresponds with this observation, LXRa ChIP-seq reads and IgG control
reads were visualised around peak intervals. Heatmap visualisation showed first that
the oxLDL top clusters have strong enrichments of corresponding IgG-derived and
T0901317-derived tags (Figure 19D, *), and second that the bottom cluster showed
comparable low tag enrichments in both treatments. To tackle that issue, top cluster
peaks were discarded by individual inspection and the bottom cluster peaks were
sub-clustered and filtered for the most enriched regions. The applied method does not
rule out the possibility that some true binding sites were missed due to the incomplete
splitting of large clusters (Duda et al. 2000). However, peak filtering resulted in a total
of 249 and 215 peaks for TO901317-treated macrophages and foam cells respectively
(Figure 4) Those peak sets were used for down stream analysis.
5.4 Formaldehyde Assisted Isolation of Regulatory Elements (FAIRE)
FAIRE was done essentially as described (Giresi and Lieb 2009) with slide modifications
using materials of the Transcription Factor ChIP Kit from Diagenode (Cat. No. kch-red
TBP-012). Cells were cross-linked and chromatin was fragmented as described for the
ChIP assay. To a 30 µl aliquot of chromatin (adjusted to 350 ng/µl DNA) 170 µl buffer
F and 8 µl 5 M NaCl was added. For FAIRE analysis of primary macrophages 15 µl
chromatin was used and the volume was adjusted to 30µl with water. An input sample
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was prepared as follows. Samples were incubated over night at 65°C and 600rpm using
a thermo shaker (TS-100, Biolabo Scientific Instruments) to reverse the chemical cross-
linking followed by incubation for 2 hours at 55°C and 500 rpm in the presence of 20 µg
Proteinase K (Invitrogen, 25530-049). Input sample and FAIRE sample were diluted
with an equal volume of water (200 µl). The FAIRE sample was incubated at 37°C
until the solution was cleared from SDS precipitations. Chromatin from Input and
FAIRE sample was extracted by adding an equal volume of phenol-chloroform/isoamyl
alcohol (25:24:1), mixing, 5 minutes incubating at room temperature and spinning
for 5 minutes at 18500g. The aqueous phase was transferred to a new DNA low bind
tube (DNA LoBind, Eppendorf) and water was added to gain a volume of 400 ul. A
second phenol-chloroform and two subsequent chloroform/isoamyl alcohol extractions
were performed to ensure all protein has been removed. The DNA was precipitated by
addition of 0.0125 volumes of DNA co-precipitant (Diagenode), 0.1 volumes of DNA
precipitant (Diagenode), twice the volume of 100% ice cold ethanol and incubation at
-20°C for 2.5 hours. The precipitate was then spun at 20000g for 45 minutes at 4°C.
The pellet was washed with 1 ml 70% room temperature ethanol and spun (30 minutes
at 18500g at room temperature). Subsequently, all liquid was removed and the pellet
was dried for 20 minutes and resuspended in 50 µl water. After addition of 350 µl
Buffer F and 16 µl 5 M NaCl samples were incubated over night at 65°C and 600 rpm.
Afterwards samples were subjected to RNaseA (10 µg) digest at 37°C and 500 rpm for
30 minutes and subsequent incubation with 40 µg Proteinase K for 2 hours at 55°C and
500 rpm. DNA was finally purified using the MinElute PCR purification kit (Qiagen)
and eluted with 30µl water. The DNA concentration was assessed using the NanoDrop
spectrophotometer (ND-1000; Nanodrop Technology). DNA fragmentation was tested
as described for the ChIP assay. DNA fragments isolated by FAIRE are 100-200 bp in
length, with the average length being 135 bp.
5.4.1 FAIRE-sequencing (FAIRE-seq)
FAIRE enriched DNA from T0901317-treated foam cells and three biological replicates
of DMSO and T0901317-treated THP-1-derived macrophages was individually pooled,
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adjusted to 8 ng/µl DNA and 150 ng DNA was provided for high-throughput sequencing.
Sample preparation and sequencing was performed by the in house NGS Sequencing
Core facility at the Max Planck Institute for Molecular Genetics. Sample preparation
was carried out by the use of the ChIP-Seq Sample Prep Kit (Illumina). Libraries
were generated from gel-purified ~200-bp DNA fragments. After adaptor ligation and
PCR-based amplification, samples were sequenced on the Illumina Genome Analyzer
IIx using standard procedures to produce short reads of 36 bp.
5.5 FAIRE-seq data analysis
5.5.1 Mapping of sequencing data
Mapping was done as described for the ChIP-seq data analysis.
5.5.2 Generation of tag signal profiles
Aligned sequencing tags were converted to a continuous wiggle track with 25 bp
resolution using F-Seq that employs Parzen kernel density estimation to create base
pair scores (Boyle et al. 2008). The exact command used for this step is:
fseq -l 800 -s 25 -v -of wig alignment.bed
Where the alignments.bed is a bed file of filtered sequence alignments. The resulting
fixed step .wig files per chromosome were concatenated using the Unix command ’cat’.
Files were further processed using the Unix command ’sed’ to make files compatible
for wig-to-bigWig conversion by the use of the program wigToBigWig (Kent et al. 2010).
BigWig files were uploaded to a webserver and visualized as custom tracks in the
UCSC Genome Browser (Karolchik et al. 2011 ).
5.5.3 Determination of FAIRE-seq enrichments
Peak intervals that represent sites of FAIRE-seq enrichments were assessed with
F-Seq (Boyle et al. 2008). The standard derivations were set for each sample using
an empirical estimation of the upper bounds on the number of nucleosome-depleted
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regions genome-wide (roughly 200,000) (Gaulton et al. 2010). The exact command used
for this step is:
fseq -t <s.d.> -l 800 -o alignment.bed
Where the alignments.bed is a bed file of filtered sequence alignments and <s.d.> is
the standard deviation. For data from vehicle-treated THP-1-derived macrophages,
the threshold used was s.d. = 3.75. For data from T0901317-treated THP-1-derived
macrophages and foam cells, the threshold used was s.d. = 4. Clusters of determined
enrichment intervals were defined by merging the determined enrichment intervals
with a maximum distance of 250 bp between intervals into single intervals that span
the entire cluster using windowBed (BEDtools) (Quinlan and Hall 2010). The sizes of
the intervals were further increased by 250bp using slopBed (BEDtools) (Quinlan and
Hall 2010). These intervals represent a liberal set of sites of open chromatin and were
used for down-stream correlations.
5.6 Genome-wide gene expression analysis
Genome-wide gene expression analysis was previously done in our lab. Therefore,
biotin-labelled cRNA was produced using the Illumina TotalPrep RNA Amplification
Kit (Ambion) according to the manufacturers instructions. Cy3-stained cRNA was
hybridised on HumanHT-12 v3 Expression BeadChips (Illumina). Scanning was
performed using the Illumina BeadStation 50 (Illumina, San Diego, CA, USA) platform
and reagents according to the protocols supplied by the manufacturer. Samples were
hybridised in biological quadruplicates. Basic expression data analysis was carried
out using BeadStudio 3.1 (Illumina Software). Raw data were background-subtracted
and normalized using the cubic spline algorithm. Processed data were then filtered for
significant detection (P-value < 0.01) and differential expression vs. vehicle treatment
according to the Illumina t-test error model and were corrected according to the
Benjamini-Hochberg procedure (P-values < 0,05) in the BeadStudio software.
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5.7 Quantitative real-time PCR (qPCR)
To assay for the enrichment of ChIP- or FAIRE-derived DNA at regions of interest
quantitative PCRs were carried out in triplicates in 384-format PCR plates. Primers
are presented in Table 8. A 5-ml reaction mixture contained a minimum of 20 pg
DNA for ChIP or 150pg for FAIRE per PCR reaction, 0.5 mM of each primer and
2× SYBR Green PCR Master Mix (Applied Biosystems, 4309155). To normalize for
primer efficacy qPCR was carried out for each primer pair using diluted input DNA and
IgG-derived DNA (ChIP only). The 7900HT Abi Prism PCR Instrument was applied
with the following parameters. The thermal cycle started with an initial denaturation
at 95°C for 10 minutes, followed by 45 cycles of denaturation at 95°C for 15 s, annealing
and extension at 60°C for 60 s. DNA melting curve analysis was performed for each
PCR reaction at temperatures ranging from 60°C to 99°C to assure that a single band
was produced. Fluorescence was read in the linear phase and the raw data were
expressed as Ct values that had achieved the baseline. The relative enrichment of
ChIP-derived DNA was calculated using the following equation:


























Where D is the dilution factor of the input DNA.
5.8 Wetern blot analysis
Cells were harvested and nuclear extracts were prepared using NE-PER Nuclear
and Cytoplasmic Extraction Kit (Thermo Scientific, Pierce, 78833). Protein contents
were determined with the Bradford method using the Bio-Rad Protein Assay Kit
(Bio-Rad Laboratories GmbH, 500-0006). Protein concentrations were adjusted to
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Name Forward primer Reverse primer Figure 2 Figure 11
hLXRaLXRE1 CATCTGTTTCGGTCTCTTTGG GCAGATGCTCCAGTCCAGAT 1 5
hLXRaLXRE3 GGATTACAGACCCGCATCAC CCAGCAATGGTGTGTTGAAA 2 6
ABCA1_1BS CCCAGCTTCCCCATCTGCGC CCGGAGGTGGGGTGCCCAAT 3
hABCALXRE CTCACTCTCGCTCGCAATTA ACGTGCTTTCTGCTGAGTGA 4 7
ABCA1_NC AGAGCGGACCCCAAAGCTGGT GGCAGTGTGTCCAGGGCTTCC 5 8
ABCA1_2BS CGGGCTCATGCTCCACTCGG GCCGATTGCCCCACATCCCT 6
ACCA1 CGCCCCTGTCTCCCACCTCA TCGGAGGTGAACGGCCTGGA 7 9
ACCA_promotor1 CGCACTCCGGAGGGGACCAA TCACTTTGCCCGTGTGGCGC 8 10
FASN CGGGGTTACTGCCGGTCATCG GTGGGTGGACGTCCGTCTCG 9 1
SREBP1 CCGCCTTTAACCCGCTCGGTG CCCTTTAACGAAGGGGGCGGG 10
FASN_H4K20 CAGGCCAGCCCAAGAGCCAC GGGGCCACCTTTCCCCCAGA 2
SREBF1_NC TGTCCATCGACAGGGAATCAGGTGG GCTTGGTTCCATGTCAACAGCCAG 3
SREBF1_H4K20 AGGAGTGCCAGTGCTTGGTGG GTAGGGCACAATGGGGGCCC 4
















Table 8: Primers for ChIP- and FAIRE-qPCR
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23 µg per sample and were analysed by western blotting using the NuPage Bis-Tris
Electrophoresis System (Invitrogen). SDS-PAGE was carried out using NuPage 15
well Novex 4-12% Bis-Tris gels (1.0 mm) and separated proteins were plotted on
nitrocellulose membranes for 75 minutes at 400mA. After blotting membranes were
stained with Ponceau S solution (Applichem, A2935,0100) to confirm equal protein
loading and de-stained using water. After blocking of membranes (1X TBS, 0.1%
Tween-20 with 5% w/v nonfat dry milk), membranes were incubated with 1:1000 LXRa
antibody (1 ug/ul, ab 41902, Abcam, mouse) in milk powder solution at 4°C over night.
After washing the membranes with TBS-Tween solution, membranes were incubated
with 1:2000 goat anti-mouse IgG-HRP andtibody (Santa Cruz Biotechnology, sc-2005)
for 1 hour at room temperature. After washing steps luminescence was detected,
membranes were striped using Restore Plus Western Blot Stripping Buffer (Thermo
Scientific) and incubated with b-Actin (C4) antibody (Santa Cruz Biotechnology sc-
47778) for 20 minutes at room temperature. After washing steps the membrane was
incubated with 1:2000 goat anti-mouse IgG-HRP andtibody (Santa Cruz Biotechnology,
sc-2005) for 20 hour at room temperature.
5.9 Bioinformatics methods
Visualisation MACS-derived peak intervals in the BED format were visualized as a
custom tracks in the UCSC genome browser (Karolchik et al. 2011). Box plots were
generated using R (RDCT 2011) or Graphpad Prism. Bar plots were generated using
Graphpad Prism. Heat maps of tag densities or genomic intervals were generated
using SeqMiner (Ye et al. 2011).
Intersection of genomic interval Genomic intervals were intersected using inter-
sectBed from the BEDtools suite (Quinlan and Hall 2010) or via Galaxy (main.g2.bx.psu.edu).
The statistical significance of co-occurrence of intervals was calculated using the R
package Cooccur (Version 0.54) (Huen and Russell 2010). Therefore, .bed files were
converted to .gff files using Galaxy (main.g2.bx.psu.edu).
73
Generation of average score profiles Average tag counts (Figure5 B) were cal-
culated using the SitePro tool from Galaxy/Cistrome (cistrome.org) and data was
visualised using R (RDCT 2011).
Determination of genomic disribution of peak intervals Genomic distribu-
tions (Figure 6) were determined using the Cis-regulatory Element Annotation System
(CEAS 1.0.2, http://liulab.dfci.harvard.edu/CEAS).
Quantitative determination of enrichments The program bigWigSummary
(Kent et al. 2010) was used to retrieve signals from wiggle or bedGraph files based on
genomic coordinates of LXRa peak intervals or intervals of open chromatin. The exact
command used for this step is:
bigWigSummary density.bigwig <chr> <start> <end> 1 type=mean
Where the density.bigwig is a bigwig file generated from filtered sequence alignments,
<chr> is the chromosome, and <start> and <end> are the starting and ending positions
of the interval, respectively.
Annotation of peak intervals to genes As described, three methods were used to
annotate LXRa peak intervals to putatively regulated genes. Nearest gene analysis was
performed using closetsBed from the BEDtools suite (Quinlan and Hall 2010). Gene
definitions were taken from the UCSC Genome Browser’s RefGene table (Fujita et al.
2010). Annotation of peak surround genes was done using the Peak Center Annotation
script (peak2gene) from the Cistrome Analysis Pipeline (AP) Module (cistrome.org)
with a distance of 30 kb from the peak centre. Association of peak intervals with genes
in regulatory domains was done using GREAT (McLean et al. 2010). Genes of all three
sets were concatenated and filtered for unique entries using the Unix command ’uniq’.
Random intervals Random intervals were generated using shufleBed from the
BEDtools suite (Quinlan and Hall 2010).
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Jaccard Matrix Similarity coefficient matrix (Figure 13) was generated using the
ChIPseeqerComputeJaccardIndex tool from ChIPseeqer (Giannopoulou and Elemento
2011) and R (RDCT 2011) for visualisation.
Gene ontology analysis To classify functions for the genes targeted by LXRa Gene
Ontology (GO) enrichment analysis was performed using the Database for Annotation,
Visualization, and Integrated Discovery (DAVID) (Huang et al. 2009a). Redundant
categories were manually removed and only the top ranked hits from each cluster were
presented.
Network analysis PWM based network analysis (Figure 8) was done using the tool
ChIP-Array (Qin et al. 2011). Interaction networks (Figue 9 and 10) were derived
from the FANTOM4-EdgeExpress Database (Kawaji et al. 2010) as described in the
corresponding section. Networks (Figure 8, 9 and 10) were visualised using Cytoscape
(Smoot et al. 2011).
Motif analysis De novo motif search was done using the MEME suite (Machanick
and Bailey 2011).
Over-representation analysis Transcription factor over-representation analysis
was done using F-MATCH (http://www.gene-regulation.com).
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